Prof Alan Thompson

Photo

Personal Profile

Name: Alan Thompson Email: alan.thompson@ucl.ac.uk
Title: Prof Tel: 020 7679 6924
Department: Faculty of Brain Sciences Fax:
Position: Garfield Weston Professor of Clinical Neurology & Neurorehabilitation Address: Department of Brain Repair and Rehabilitation, Queen Square, London, WC1N 3BG
Research Domain: Biomedical Imaging (Frontier Disciplines), Neuroscience, Personalised Medicine Web Page: Personal Web Page

Profile

Research Description

Heads group using magnetic resonance imaging (MRI) to evaluate the underlying pathology of multiple sclerosis (MS), measure brain atrophy, and establish reliable markers for disease progression and extent of disability.  Methods are being developed to measure grey matter atrophy and abnormalities accurately, which, when incorporated into clinical trials as an outcome measure, will allow effective treatments to be identified, and show the likely relationship between grey matter atrophy and physical disability and cognitive impairment.




With Dr Olga Ciccarelli studies mechanisms of damage in acute lesions affecting the motor tracts and, in particular, the effect they have on the axons that traverse them.  New research hopes to establish the role of mitochondrial dysfunction in MS and whether the reversibility of mitochondrial dysfunction causes clinical improvement in MS patients.    With Dr Ahmed Toosy studies structural/functional recovery mechanisms following optic neuritis to develop new strategies to enhance recovery and identify effective treatments.  Collaborates with Dr Patrick Freund and team using imaging to identify morphometric changes which may predict clinical recovery after spinal cord injury.  Supports Bernadette Porter, MS Nurse Consultant, in developing NeuroResponse, providing high quality telecare to patients with MS.




Member of international group of experts who have published criteria for the diagnosis of MS.  Leads research to define the imaging characteristics, diagnostic criteria, and underlying disease progression for primary progressive multiple sclerosis, using a unique cohort of patients.




As Programme Director for the Neurological Disorders theme for UCL Partners oversees development of the stroke service, applying a quality metric across the entire pathway with Dr Charlie Davie.  A combined research and clinical strategy for brain cancer has culminated in a unified, single-site neurosurgical service and a dedicated Brain Tumour Centre for North Central London, and a collaborative research programme with the Cancer Institute.  Work continues to commission the entire pathway and to identify quality metrics.  Research into neurodegenerative disease is developing to enhance understanding, diagnosis, and treatment, and to create a dedicated national resource for testing novel therapies.  Using a combination of novel biomarkers, at-risk cohorts, and sensitive and precise measures of progression, early proof of concept studies are planned which will involve an interdisciplinary, cross-disease approach to identify potential disease-modifying therapies.




Work on Neurological Outcome Measures focuses on the development, evaluation, and application of rating scales to measure health outcomes, predominantly from the patients' perspective.  Amongst the achievements are the MS Walking Scale, which contributed to the recent approval of a symptomatic treatment for MS (Fampridine), validation of a generic walking scale, and the MS Impact Scale (MSIS-29 with Professor Jeremy Hobart), The MS Impact Scale and the MS Walking Scale are used in clinical trials and epidemiological studies world-wide.




In neurological disability management, Alan Thompson has worked on Quality Standards (2005); the MS World Atlas (with WHO/MSIF, 2008), and the Global Economic Study (with MSIF, 2010).  He is currently part of the WHO Advisory Group revising the ICD-10 for Neurological Disorders.  The Neurological Rehabilitation Unit studies goal-setting and vocational rehabilitation (Dr Diane Playford), treatment of MS relapses (Dr Jeremy Chataway, Bernie Porter), and spasticity (Dr Val Stevenson).    









 


Research Activities

Clinical Neurology

MRI-Magnetic Resonance Imaging

Multiple Sclerosis

Neurological Outcomes Measures

Neuromuscular and Neurodegenerative Disorders

Education Description

Involved in multidisciplinary teaching to medical students, post-graduate students, nurses and therapists, focusing on MRI, neurorehabilitation, and the management of disability; special focus on multiple sclerosis.
Participates in short courses run by Institute of Neurology.
As Director of Institute of Neurology fostered growth of the Education Unit to establish a four-year PhD programme in Clinical Neuroscience, a new MSc course in Advanced Neuroimaging, an online MSc for neurology trainees, and developing a distance learning postgraduate diploma in neuroscience (e-Brain) with the Joint Neurosciences Council and the EFNS.  Within the CBRC launched an MSc in Translational Medicine. 
Established National Treasure post in neurorehabilitation and curriculum for neurology SpRs in last year of training.
As Medical Advisor to the MS Society and now the MSIF, involved in production of educational materials for patients relating to diagnosis, treatment and management of MS.
International teaching role:  Teaches regularly in courses and workshops on neurorehabilitation, outcome measurement, MRI, and diagnosis and management of multiple sclerosis aimed at researchers, physicians, specialist nurses, therapists, and patient groups.  Named lectures include the Gowers Memorial Lecture Queen Square, May 2009, and the BS Singhal Oration at the ABN/Indian Neurological Association meeting, Mumbai, 2007.
Has edited textbooks on multiple sclerosis and is editor-in-chief of Multiple Sclerosis Journal.

UCL Collaborators

Prof John Hardy; Dr Richard Orrell; Prof David Selwood; Prof Elizabeth Fisher; Dr Kirsi Kinnunen; Prof Linda Greensmith; Dr Shi-Yu Yang; Prof Niall Quinn; Prof Francesco Muntoni; Dr David Thomas

External Collaborators

Publications

    2014

    • Tur C, Ramagopalan S, Altmann DR, Bodini B, Cercignani M, Khaleeli Z, Miller DH, Thompson AJ, Ciccarelli O (2014). HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.. Neurology, , - . doi:10.1212/WNL.0000000000000959
    • Abdel-Aziz K, Solanky BS, Yiannakas MC, Altmann DR, Wheeler-Kingshott CA, Thompson AJ, Ciccarelli O (2014). Age related changes in metabolite concentrations in the normal spinal cord.. PLoS One, 9(10), e105774 - . doi:10.1371/journal.pone.0105774
    • Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ (2014). Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.. Neurology, 83(11), 1022 - 1024. doi:10.1212/WNL.0000000000000768
    • Toosy AT, Kou N, Altmann D, Wheeler-Kingshott CA, Thompson AJ, Ciccarelli O (2014). Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis.. Neurology, , - . doi:10.1212/WNL.0000000000000857
    • Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014). Defining the clinical course of multiple sclerosis: The 2013 revisions.. Neurology, , - . doi:10.1212/WNL.0000000000000560
    • Tur C, Wheeler-Kingshott CA, Altmann DR, Miller DH, Thompson AJ, Ciccarelli O (2014). Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI.. Hum Brain Mapp, 35(3), 993 - 1003. doi:10.1002/hbm.22229
    • Muhlert N, Atzori M, De Vita E, Thomas DL, Samson RS, Wheeler-Kingshott CA, Geurts JJ, Miller DH, Thompson AJ, Ciccarelli O (2014). Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions.. J Neurol Neurosurg Psychiatry, , - . doi:10.1136/jnnp-2013-306662
    • Meijer KA, Cercignani M, Muhlert N, Sethi V, Chard D, Ron M, Thompson AJ, Miller DH, Geurts JJG, Ciccarelli O (2014). White matter abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis..
    • Meijer KA, Cercignani M, Muhlert N, Sethi V, Chard D, Ron M, Thompson AJ, Miller DH, Geurts JJG, Ciccarelli O (2014). Independent component analysis of DTI metrics in multiple sclerosis..
    • Cawley N, Solanky B, Muhlert N, Wheeler-Kingshott CAM, Thompson AJ, Ciccarelli O (2014). Quantification of GABA in the grey matter in multiple sclerosis..
    • Toosy A, Ciccarelli O, Thompson A (2014). Symptomatic treatment and management of multiple sclerosis.. Handb Clin Neurol, 122, 513 - 562. doi:10.1016/B978-0-444-52001-2.00023-6

    2013

    • Kachramanoglou C, De Vita E, Thomas DL, Wheeler-Kingshott CAM, Balteau E, Carlstedt T, Choi D, Thompson AJ, Ciccarelli O (2013). Metabolic Changes in the Spinal Cord After Brachial Plexus Root Re-implantation. NEUROREHABILITATION AND NEURAL REPAIR, 27(2), 118 - 124. doi:10.1177/1545968312457825
    • Bodini B, Cercignani M, Khaleeli Z, Miller DH, Ron M, Penny S, Thompson AJ, Ciccarelli O (2013). Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years.. Hum Brain Mapp, 34(5), 1163 - 1172. doi:10.1002/hbm.21499
    • Stroman PW, Wheeler-Kingshott C, Bacon M, Schwab JM, Bosma R, Brooks J, Cadotte D, Carlstedt T, Ciccarelli O, Cohen-Adad J, Curt A, Evangelou N, Fehlings MG, Filippi M, Kelly B, Kollias S, Mackay A, Porro CA, Smith S, Strittmatter SM, Summers P, Tracey I (2013). The current state-of-the-art of spinal cord imaging: Methods.. Neuroimage, , - . doi:10.1016/j.neuroimage.2013.04.124
    • Ciccarelli O, Thomas DL, De Vita E, Wheeler-Kingshott CA, Kachramanoglou C, Kapoor R, Leary S, Matthews L, Palace J, Chard D, Miller DH, Toosy AT, Thompson AJ (2013). Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica.. Ann Neurol, 74(2), 301 - 305. doi:10.1002/ana.23909
    • Freund P, Curt A, Friston K, Thompson A (2013). Tracking changes following spinal cord injury: insights from neuroimaging.. Neuroscientist, 19(2), 116 - 128. doi:10.1177/1073858412449192
    • Thompson A, Antel J, Carroll W (2013). Message from the editors.. Mult Scler, 19(1), 2 - . doi:10.1177/1352458512473206
    • Van de Pavert SHP, Muhlert N, Sethi V, Wheeler-Kingshott CA, Thompson AJ, Geurts JJG, Yousry TA, Miller DH, Chard DT, Ciccarelli O (2013). Co-localisation and clinical impact of grey matter lesions and regional grey matter volume loss in multiple sclerosis..
    • Hunter RM, Davie C, Rudd A, Thompson A, Walker H, Thomson N, Mountford J, Schwamm L, Deanfield J, Thompson K, Dewan B, Mistry M, Quoraishi S, Morris S (2013). Impact on clinical and cost outcomes of a centralized approach to acute stroke care in london: a comparative effectiveness before and after model.. PLoS One, 8(8), e70420 - . doi:10.1371/journal.pone.0070420
    • Tur C, Ramagopalan S, Altmann DR, Bodini B, Cercignani M, Khaleeli Z, Miller DH, Thompson AJ, Ciccarelli O (2013). HLA-DRB1*15 influences the development of brain tissue damage in early primary progressive multiple sclerosis..
    • Bodini B, Chard D, Altmann D, Miller DH, Thompson AJ, Wheeler-Kingshott C, Ciccarelli O (2013). White and grey matter damage in early primary-progressive multiple sclerosis: the chicken or the egg?.
    • Freund P, Weiskopf N, Ashburner J, Wolf K, Sutter R, Altmann DR, Friston K, Thompson A, Curt A (2013). MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study. The Lancet Neurology, , - .
    • Bodini B, Cercignani M, Toosy A, De Stefano N, Miller DH , Thompson AJ, Ciccarelli O (2013). A novel approach with “skeletonised MTR” measures tract-specific microstructural changes in early primary-progressive MS. Human Brain Mapping, , - . doi:10.1002/hbm.22196
    • Kachramanoglou C, De Vita E, Thomas DL, Wheeler-Kingshott CA, Balteau E, Carlstedt T, Choi D, Thompson AJ, Ciccarelli O (2013). Metabolic changes in the spinal cord after brachial plexus root re-implantation.. Neurorehabil Neural Repair, 27(2), 118 - 124. doi:10.1177/1545968312457825
    • Thompson AJ, Chandraratna D (2013). Multiple Sclerosis International Federation: Stimulating international cooperation in research.. Neurology, 81(20), 1793 - 1795. doi:10.1212/01.wnl.0000435552.67953.c8
    • Eshaghi A, Bodini B, Ridgway GR, García-Lorenzo D, Tozer D, Sahraian MA, Thompson AJ, Ciccarelli O (2013). Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis.. Neuroimage, , - . doi:10.1016/j.neuroimage.2013.09.059
    • Wheeler-Kingshott C, Stroman PW, Schwab JM, Bacon M, Bosma R, Brooks J, Cadotte DW, Carlstedt T, Ciccarelli O, Cohen-Adad J, Curt A, Evangelou N, Fehlings MG, Filippi M, Kelley BJ, Kollias S, Mackay A, Porro CA, Smith S, Strittmatter SM, Summers P, Thompson AJ, Tracey I (2013). The current state-of-the-art of spinal cord imaging - Applications.. Neuroimage, , - . doi:10.1016/j.neuroimage.2013.07.014
    • Thompson AJ, Giovannoni G (2013). Removal of access to alemtuzumab for patients with aggressive multiple sclerosis.. BMJ, 346, f275 - .
    • Abdel-Aziz K, Solanky BS, Wheeler-Kingshott CAM, Cawley N, Yiannakas MC, Thompson AJ, Ciccarelli O (2013). Evidence for early neuronal damage in the cervical cord of patients with primary progressive multiple sclerosis..

    2012

    • Fox RJ, Thompson A, Baker D, Baneke P, Browne D, Chandraratna D, Ciccarelli O, Coetzee T, Comi G, Feinstein A, Kapoor R, Lee K, Salvetti M, Sharrock K, Toosy A, Zaratin P, Zuidwijk K (2012). Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. Multiple Sclerosis, , - .
    • Freund P, Schneider T, Nagy Z, Hutton C, Weiskopf N, Friston K, Wheeler-Kingshott CAM, Thompson A (2012). Degeneration of the injured cervical cord is associated with remote changes in corticospinal tract integrity and upper limb impairment. PLoS One, 7((12)), e51729 - . doi:10.1371/journal.pone.0051729.
    • Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du M-Q, Luan S-L, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S (2012). Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurology, 11(2), 150 - 156. doi:10.1016/S1474-4422(11)70305-2
    • Freund P, Wheeler-Kingshott CA, Nagy Z, Gorgoraptis N, Weiskopf N, Friston K, Thompson AJ, Hutton C (2012). Axonal integrity predicts cortical reorganisation following cervical injury.. J Neurol Neurosurg Psychiatry, 83(6), 629 - 637. doi:10.1136/jnnp-2011-301875
    • Marsden J, Ramdharry G, Stevenson V, Thompson A (2012). Muscle paresis and passive stiffness: Key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis. GAIT & POSTURE, 35(2), 266 - 271. doi:10.1016/j.gaitpost.2011.09.018
    • Porter B, Thompson A (2012). Connecting to the future - the promise of telecare. MULTIPLE SCLEROSIS JOURNAL, 18(4), 384 - 386. doi:10.1177/1352458512441273
    • Tozer DJ, Chard DT, Bodini B, Ciccarelli O, Miller DH, Thompson AJ, Wheeler-Kingshott CAM (2012). Linking white matter tracts to associated cortical grey matter: a tract extension methodology. NeuroImage, 59(4), 3094 - 3102. doi:10.1016/j.neuroimage.2011.10.088
    • Morley D, Selai C, Thompson A (2012). The self-report Barthel Index: preliminary validation in people with Parkinson's disease.. Eur J Neurol, 19(6), 927 - 929. doi:10.1111/j.1468-1331.2011.03592.x
    • Dalton CM, Bodini B, Samson RS, Battaglini M, Fisniku LK, Thompson AJ, Ciccarelli O, Miller DH, Chard DT (2012). Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis.. Mult Scler, 18(3), 322 - 328. doi:10.1177/1352458511420269
    • Cohen JA, Reingold SC, Polman CH, Wolinsky JS, Int Adv Cmmttee on Clinical Trials in MS (2012). Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurology, 11(5), 467 - 476. doi:10.1016/S1474-4422(12)70059-5
    • Schofield TM, Penny WD, Stephan KE, Crinion JT, Thompson AJ, Price CJ, Leff AP (2012). Changes in auditory feedback connections determine the severity of speech processing deficits after stroke.. J Neurosci, 32(12), 4260 - 4270. doi:10.1523/JNEUROSCI.4670-11.2012

    2011

    • Jenkins TM, Ciccarelli O, Atzori M, Wheeler-Kingshott CAM, Miller DH, Thompson AJ, Toosy AT (2011). Early pericalcarine atrophy in acute optice neuritis is associated with conversion to MS..
    • Bonati U, Fisniku LK, Altmann DR, Yiannakas MC, Furby J, Thompson AJ, Miller DH, Chard DT (2011). Cervical cord and brain grey matter atrophy independently associate with long-term MS disability.. J Neurol Neurosurg Psychiatry, 82(4), 471 - 472. doi:10.1136/jnnp.2010.205021
    • Muhlert N, Atzori M, De Vita E, Thomas D, Geurts JJG, Wheeler-Kingshott CAM, Thompson AJ, Ciccarelli O (2011). Quantification of glutamate in the cortex, hippocampus and thalamus and its relationship with cognitive performance in MS.
    • Freund P, Weiskopf N, Ward NS, Hutton C, Gall A, Ciccarelli O, Craggs M, Friston K, Thompson AJ (2011). Disability, atrophy and cortical reorganization following spinal cord injury.. Brain, 134(Pt 6), 1610 - 1622. doi:10.1093/brain/awr093
    • Panchani J, Adjei P, Henneberger C, Scott CA, Thompson AJ, Diehl B, Walker MC, Surges R (2011). Asymmetric hemispheric representation of periictal heart rate modulation is individually lateralised.. Epileptic Disord, 13(2), 172 - 176. doi:10.1684/epd.2011.0430
    • Anderson VM, Wheeler-Kingshott CA, Abdel-Aziz K, Miller DH, Toosy A, Thompson AJ, Ciccarelli O (2011). A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis.. Mult Scler, 17(9), 1079 - 1087. doi:10.1177/1352458511403528
    • Jenkins TM, Ciccarelli O, Atzori M, Wheeler-Kingshott CA, Miller DH, Thompson AJ, Toosy AT (2011). Early pericalcarine atrophy in acute optic neuritis is associated with conversion to multiple sclerosis.. J Neurol Neurosurg Psychiatry, 82(9), 1017 - 1021. doi:10.1136/jnnp.2010.239715
    • Aguirregomozcorta M, Mancini L, Jenkins TM, Hickman SJ, Ciccarelli O, Plant GT, Thompson AJ, Toosy AT (2011). A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients.. J Neurol Neurosurg Psychiatry, 82(8), 905 - 913. doi:10.1136/jnnp.2009.194563
    • Morley D, Selai C, Schrag A, Jahanshahi M, Thompson A (2011). Adolescent and adult children of parents with Parkinson's disease: incorporating their needs in clinical guidelines.. Parkinsons Dis, 2011, 951874 - . doi:10.4061/2011/951874
    • Hardy J, Thompson AJ (2011). Dissecting the familial risk of multiple sclerosis.. Ann Neurol, 69(1), 11 - 12. doi:10.1002/ana.22353
    • Bodini B, Battaglini M, De Stefano N, Khaleeli Z, Barkhof F, Chard D, Filippi M, Montalban X, Polman C, Rovaris M, Rovira A, Samson R, Miller D, Thompson A, Ciccarelli O (2011). T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis.. J Neurol Neurosurg Psychiatry, 82(1), 72 - 77. doi:10.1136/jnnp.2009.201574
    • Isaacs JD, Bodini B, Ciccarelli O, Scadding GK, Thompson AJ (2011). Atopic myelitis in a European woman residing in Japan.. J Neurol Neurosurg Psychiatry, 82(9), 1022 - 1024. doi:10.1136/jnnp.2009.186775
    • Tur C, Penny S, Khaleeli Z, Altmann DR, Cipolotti L, Ron M, Thompson AJ, Ciccarelli O (2011). Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis.. Mult Scler, 17(11), 1324 - 1332. doi:10.1177/1352458511410341
    • Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S (2011). The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.. Trials, 12, 62 - . doi:10.1186/1745-6215-12-62
    • Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011). Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. ANN NEUROL, 69(2), 292 - 302. doi:10.1002/ana.22366
    • Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ, Plant GT, Miller DH (2011). MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J NEUROL NEUROSUR PS, 82(2), 176 - 179. doi:10.1136/jnnp.2010.208660
    • Riazi A, Porter B, Chataway J, Thompson AJ, Hobart JC (2011). A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS).. Health Qual Life Outcomes, 9, 80 - . doi:10.1186/1477-7525-9-80
    • Freund P, Rothwell JC, Craggs M, Thompson AJ, Bestmann S (2011). Corticomotor representation to human arm muscle changes following cervical spinal cord injury. European Journal of Neuroscience, , - . doi:10.1111/j.1460-9568.2011.07895.x
    • Tur C, Khaleeli Z, Ciccarelli O, Altmann DR, Cercignani M, Miller DH, Thompson AJ (2011). Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS.. J Neurol Neurosurg Psychiatry, 82(4), 423 - 428. doi:10.1136/jnnp.2010.209890
    • Atzori M, Muhlert N, De Vita E, Thomas D, Geurts JJG, Wheeler-Kingshott CAM, Thompson AJ, Ciccarelli O (2011). Quantification of glutamate in the cortex, hippocampus and thalamus and its relationship with cognitive performance in MS.

    2010

    • Thompson AJ, Toosy AT, Ciccarelli O (2010). Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.. Lancet Neurol, 9(12), 1182 - 1199. doi:10.1016/S1474-4422(10)70249-0
    • Jenkins T, Ciccarelli O, Toosy A, Miszkiel K, Wheeler-Kingshott C, Altmann D, Mancini L, Jones S, Plant G, Miller DH, Thompson AJ (2010). Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity. Human Brain Mapping, 31, 276 - 286.
    • Freund PA, Dalton C, Wheeler-Kingshott CA, Glensman J, Bradbury D, Thompson AJ, Weiskopf N (2010). Method for simultaneous voxel-based morphometry of the brain and cervical spinal cord area measurements using 3D-MDEFT.. J Magn Reson Imaging, 32(5), 1242 - 1247. doi:10.1002/jmri.22340
    • Thompson A (2010). MS neuro-rehabilitation: Changes and challenges.
    • Freund P, Wheeler-Kingshott C, Jackson J, Miller D, Thompson A, Ciccarelli O (2010). Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity.. Mult Scler, 16(10), 1193 - 1202. doi:10.1177/1352458510376180
    • Antel J, Thompson A, Carroll W (2010). Chronic cerebrospinal venous insufficiency. MULT SCLER, 16(7), 770 - 770. doi:10.1177/1352458510374342
    • Gorgoraptis N, Wheeler-Kingshott CAM, Jenkins TM, Altmann DR, Miller DH, Thompson AJ, Ciccarelli O (2010). Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis. Multiple Sclerosis, 16(5), 555 - 565. doi:10.1177/1352458510362440
    • Dobson R, Miller RF, Palmer HE, Feldmann M, Thompson EJ, Thompson AJ, Miller DH, Giovannoni G (2010). Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. J NEUROIMMUNOL, 220(1-2), 99 - 103. doi:10.1016/j.jneuroim.2010.01.012
    • Khaleeli Z, Ciccarelli O, Mizskiel K, Altmann D, Miller DH, Thompson AJ (2010). Lesion enhancement diminishes with time in primary progressive multiple sclerosis.. Mult Scler, 16(3), 317 - 324. doi:10.1177/1352458509358090
    • Morley D, Selai C, Schrag A, Thompson AJ, Jahanshahi M (2010). Refinement and validation of the Parental Illness Impact Scale.. Parkinsonism Relat Disord, 16(3), 181 - 185. doi:10.1016/j.parkreldis.2009.11.001
    • Penny S, Khaleeli Z, Cipolotti L, Thompson A, Ron M (2010). Early imaging predicts later cognitive impairment in primary progressive multiple sclerosis.. Neurology, 74(7), 545 - 552. doi:10.1212/WNL.0b013e3181cff6a6
    • Montalban X, Tintore M, Swanton J, Barkhof F, Fazekas F, Filippi M, Frederiksen J, Kappos L, Palace J, Polman C, Rovaris M, de Stefano N, Thompson A, Yousry T, Rovira A, Miller DH (2010). MRI criteria for MS in patients with clinically isolated syndromes. NEUROLOGY, 74(5), 427 - 434. doi:10.1212/WNL.0b013e3181cec45c
    • Thompson A (2010). Development of Neuroimaging in Multiple Sclerosis.
    • Ciccarelli O, Altmann DR, McLean MA, Wheeler-Kingshott CA, Wimpey K, Miller DH, Thompson AJ (2010). Spinal cord repair in MS: does mitochondrial metabolism play a role?. Neurology, 74(9), 721 - 727. doi:10.1212/WNL.0b013e3181d26968
    • Jenkins TM, Toosy AT, Ciccarelli O, Miszkiel KA, Wheeler-Kingshott CA, Henderson AP, Kallis C, Mancini L, Plant GT, Miller DH, Thompson AJ (2010). Neuroplasticity predicts outcome of optic neuritis independent of tissue damage.. Ann Neurol, 67(1), 99 - 113. doi:10.1002/ana.21823
    • Jenkins T, Toosy AT, Ciccarelli O, Miszkiel KA, Wheeler-Kingsnott CA, Henderson AP, Kallis C, Mancini L, Plant GT, Miller DH, Thompson AJ (2010). Neuroplasticity Predicts Outcome of Optic Neuritis Independent of Tissue Damage Reply. ANN NEUROL, 68(6), 971 - 971. doi:10.1002/ana.22030
    • Hobart JC, Cano SJ, Thompson AJ (2010). Effect sizes can be misleading: is it time to change the way we measure change?. J NEUROL NEUROSUR PS, 81(9), 1044 - 1048. doi:10.1136/jnnp.2009.201392
    • Rejdak K, Leary SM, Petzold A, Thompson AJ, Miller DH, Giovannoni G (2010). Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis.. Mult Scler, 16(9), 1066 - 1072. doi:10.1177/1352458510375100
    • Anderson VM, Fisniku LK, Khaleeli Z, Summers MM, Penny SA, Altmann DR, Thompson AJ, Ron MA, Miller DH (2010). Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study.. Mult Scler, 16(9), 1083 - 1090. doi:10.1177/1352458510374893
    • Bosma LVAE, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintore M, Uitdehaag BMJ (2010). Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?. MULT SCLER, 16(7), 862 - 867. doi:10.1177/1352458510370464
    • De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, Korteweg T, Enzinger C, Fazekas F, Calabrese M, Dinacci D, Tedeschi G, Gass A, Montalban X, Rovira A, Thompson A, Comi G, Miller DH, Filippi M (2010). Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. NEUROLOGY, 74(23), 1868 - 1876. doi:10.1212/WNL.0b013e3181e24136
    • Trip SA, Schlottmann PG, Jones SJ, Kallis C, Altmann DR, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH (2010). Scanning laser polarimetry quantification of retinal nerve fiber layer thinning following optic neuritis.. J Neuroophthalmol, 30(3), 235 - 242. doi:10.1097/WNO.0b013e3181dbfeac
    • Flachenecker P, Khil L, Bergmann S, Kowalewski M, Pascu I, Perez-Miralles F, Sastre-Garriga J, Zwingers T, MS-ID Study Group (2010). Development and pilot phase of a European MS register.. J Neurol, 257, 1620 - 1627.
    • Martino G, Franklin RJM, Van Evercooren AB, Kerr DA, Stem Cells in MS Consensus Group (2010). Stem cell transplantation in multiple sclerosis: current status and future prospects. Nature Rev Neurol, 6, 247 - 255.
    • Papadopoulos K, Tozer DJ, Fisniku L, Altmann DR, Davies G, Rashid W, Thompson AJ, Miller DH, Chard DT (2010). T1-relaxation time changes over five years in relapsing-remitting multiple sclerosis. MULT SCLER, 16(4), 427 - 433. doi:10.1177/1352458509359924
    • Thompson A, Antel J, Carroll W (2010). Message from the editors.. Mult Scler, 16(3), 281 - . doi:10.1177/1352458510363837
    • Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, Thompson AJ, Miller DH (2010). Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.. Mult Scler, 16(2), 156 - 165. doi:10.1177/1352458509353650
    • Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, Thompson AJ, Miller DH (2010). Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes.. J Neurol Neurosurg Psychiatry, 81(2), 204 - 208. doi:10.1136/jnnp.2009.171769
    • Ciccarelli O, Toosy AT, De Stefano N, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2010). Assessing neuronal metabolism in vivo by modeling imaging measures.. J Neurosci, 30(45), 15030 - 15033. doi:10.1523/JNEUROSCI.3330-10.2010

    2009

    • Bodini B, Battaglini M, De Stefano N, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Polman CH, Rovaris M, Rovira A, Sastre-Garriga J, Chard D, Samson R, Miller D, Thompson AJ, Ciccarelli O (2009). Spatial localisation of lesions predicts clinical deterioration in primary progressive multiple sclerosis: a 10-year multi-centre study.
    • Thompson AJ (2009). Progressive MS seen by MRI.
    • Tozer DJ, Marongiu G, Swanton JK, Thompson AJ, Miller DH (2009). Texture analysis of magnetisation transfer maps from patients with clinically isolated syndrome and multiple sclerosis. Journal of Magnetic Resonance Imaging, 30(3), 506 - 513. doi:10.1002/jmri.21885
    • Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L, Thompson AJ, Wolinsky JS (2009). The challenge of follow-on biologics for treatment of multiple sclerosis.. Neurology, 73(7), 552 - 559. doi:10.1212/WNL.0b013e3181b2a6ce
    • Rocca MA, Absinta M, Valsasina P, Ciccarelli O, Marino S, Rovira A, Gass A, Wegner C, Enzinger C, Korteweg T, Sormani MP, Mancini L, Thompson AJ, De Stefano N, Montalban X, Hirsch J, Kappos L, Ropele S, Palace J, Barkhof F, Matthews PM, Filippi M (2009). Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study.. Human Brain Mapping, 30(8), 2412 - 2425. doi:10.1002/hbm.20679
    • Filippi M, Rocca MA, Absinta M, Valsasina P, Ciccarelli O, Marino S, Rovira A, Gass A, Wegner C, Enzinger C, Korteweg T, Mancini L, Thompson A, De Stefano N, Montalban X, Hirsch J, Kappos L, Ropele S, Palace J, Barkhof F, Yousry T, Matthews PM (2009). Functional connectivity changes of the motor network in patients with multiple sclerosis: a multi-centre fMRI study.
    • Rovaris M, Barkhof F, Calabrese M, De Stefano N, Fazekas F, Miller DH, Montalban X, Polman C, Rocca MA, Thompson AJ, Yousry TA, Filippi M (2009). MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology, 72(19), 1693 - 1701. doi:10.1212/WNL.0b013e3181a55feb
    • Mancini L, Ciccarelli O, Manfredonia F, Thornton JS, Agosta F, Barkhof F, Beckmann C, De SN, Enzinger C, Fazekas F, Filippi M, Gass A, Hirsch JG, Johansen-Berg H, Kappos L, Korteweg T, Manson SC, Marino S, Matthews PM, Montalban X, Palace J, Polman C, Rocca M, Ropele S, Rovira A, Wegner C, Friston K, Thompson A, Yousry T (2009). Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis. NeuroImage, 45(2), 500 - 511. doi:10.1016/j.neuroimage.2008.12.006
    • Kolappan M, Henderson APD, Jenkins TM, Wheeler-Kingshott CAM, Plant GT, Thompson AJ, Miller DH (2009). Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. Journal of Neurology, 256(3), 305 - 319. doi:10.1007/s00415-009-0123-z
    • Fazekas F, Thompson A (2009). New MRI techniques and "aggressive" multiple sclerosis. Multiple Sclerosis, 15(3), 283 - 284. doi:10.1177/1352458509102997
    • van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BMJ (2009). The size of the treatment effect: do patients and proxies agree?. BMC Neurology, 9, 12 - . doi:10.1186/1471-2377-9-12
    • Ciccarelli O, Behrens TE, Johansen-Berg H, Talbot K, Orrell RW, Howard RS, Nunes RG, Miller DH, Matthews PM, Thompson AJ, Smith SM (2009). Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics.. Human Brain Mapping, 30(2), 615 - 624. doi:10.1002/hbm.20527
    • Altmann DR, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos LD, Molyneux P, Polman CH, Pozzilli C, Thompson AJ, Wagner K, Yousry TA, Miller DH (2009). Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.. Neurology, 72(7), 595 - 601. doi:10.1212/01.wnl.0000335765.55346.fc
    • Fisniku LK, Jackson J, Chard D, Altmann D, Thompson AJ, Miller DH (2009). GREY MATTER AND WHITE MATTER VOLUMES AT 20 YEAR FOLLOW-UP OF A MULTIPLE SCLEROSIS AND CLINICALLY ISOLATED SYNDROME COHORT SEEN FROM ONSET.
    • Chard DT, Swanton JK, Dalton CM, Fernando KT, Miszkiel KA, Plant GT, Thompson AJ, Miller DH (2009). RADIOLOGICAL BUT NOT CLINICAL CONVERSION TO MULTIPLE SCLEROSIS FOLLOWING A CLINICALLY ISOLATED SYNDROME. doi:10.1136/jnnp.2009.195172e
    • Fisniku L, Altmann D, Brex P, Chard D, Jackson J, Miszkiel K, Thompson AJ, Miller D (2009). Changes in brain lesion load over 20 years and subsequent brain atrophy in clinically isolated syndrome patients.
    • Bodini B, Khaleeli Z, Cercignani M, Miller DH, Thompson AJ, Ciccarelli O (2009). Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM. Human Brain Mapping, 30(9), 2852 - 2861. doi:10.1002/hbm.20713
    • Rocca M, Absinta M, Valsasina P, Ciccarelli O, Marino S, Rovira A, Gass A, Wegner C, Enzinger C, Korteweg T, Mancini L, Thompson AJ, De Stefano N, Montalban X, Hirsch J, Kappos L, Ropele S, Palace J, Barkhof F, Yousry T, Matthews P, Filippi M (2009). Functional connectivity changes of the motor network in patients with multiple sclerosis: a multicentre fMRI study.
    • Tur C, Penny S, Ciccarelli O, Altmann D, Cipolotti L, Ron M, Miller D, Thompson AJ (2009). Grey matter MTR is related to cognitive impairment in primary progressive multiple sclerosis.
    • Anderson V, Fisniku L, Khaleeli Z, Summers M, Penny S, Ron M, Thompson AJ, Miller D (2009). Hippocampal volume is reduced in relapsing-remitting and primary progressive multiple sclerosis and is associated with memory impairment.
    • Dalton C, Chard D, Swanton J, Fisniku L, Miszkiel K, Thompson AJ, Plant G, Miller D (2009). Radiological-only conversion to multiple sclerosis following a clinically isolated syndrome.
    • Bodini B, Khaleeli Z, Cercignani M, Miller D, Thompson AJ, Ciccarelli O (2009). Reduced tissue integrity in the splenium of the corpus callosum predicts progression of disability over five years in early primary progressive multiple sclerosis.
    • Bonati U, Fisniku L, Altmann D, Yiannakas M, Furby J, Thompson AJ, Chard D, Miller D (2009). Cervical cord and brain grey matter atrophy, and T2 lesion load accrual, independently reflect the long-term disability in multiple sclerosis.
    • Anderson VM, Fisniku LK, Altmann DR, Thompson AJ, Miller DH (2009). MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Multiple Sclerosis, 15(7), 811 - 817. doi:10.1177/1352458508101934
    • Aguirregomozcorta M, Mancini L, Ciccarelli O, Jenkins T, Hickman S, Thompson A, Toosy A (2009). A longitudinal evaluation of the disease mechanisms of non-arteritic anterior ischaemic optic neuropathy using functional magnetic resonance imaging.
    • Fisniku LK, Altmann DR, Cercignani M, Tozer DJ, Chard DT, Jackson JS, Miszkiel KA, Schmierer K, Thompson AJ, Miller DH (2009). Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Multiple Sclerosis, 15(6), 668 - 677. doi:10.1177/1352458509103715
    • Bosma LVAE, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintore M, Uitdehaag BMJ (2009). The search for responsive clinical endpoints in primary progressive multiple sclerosis. Multiple Sclerosis, 15(6), 715 - 720. doi:10.1177/1352458509102626
    • Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, Thompson AJ, Miller DH (2009). Early MRI in optic neuritis: The risk for disability. Neurology, 72(6), 542 - 550. doi:10.1212/01.wnl.0000341935.41852.82
    • Altmann DR, Miszkiel KA, Thompson AJ (2009). Gray Matter Atrophy Is Related to Long-Term Disability in Multiple Sclerosis (vol 64, pg 247, 2008). ANN NEUROL, 65(2), 232 - 232. doi:10.1002/ana.21570
    • Thompson A, Polman C (2009). Improving function: a new treatment era for multiple sclerosis?. The Lancet, 373(9665), 697 - 698. doi:10.1016/S0140-6736(09)60414-1
    • Leary S, Giovannoni G, Howard R, Miller D, Thompson A (2009). Multiple sclerosis and demyelinating diseases. In Clarke C, Howard R, Rossor M, Shorvon S (Ed.), Neurology: a Queen Square textbook (pp. 411 - 447). : Wiley-Blackwell.
    • Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ (2009). Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.. Mult Scler, 15(12), 1459 - 1465. doi:10.1177/1352458509348422
    • Papadopoulos K, Tozer D, Fisniku L, Altmann D, Davies G, Rashid W, Thompson AJ, Miller D, Chard D (2009). Progressive normal-appearing white matter and grey matter T1 relaxation time abnormalities over 5 years in relapsing-remitting multiple sclerosis.
    • Tur C, Khaleeli Z, Ciccarelli O, Altmann D, Cercignani M, Miller D, Thompson AJ (2009). Complementary roles of grey matter MTR and T2 lesion load in determining disability in early primary progressive multiple sclerosis-5-year follow-up study.
    • Jenkins TM, Thompson AJ (2009). Diagnosing and managing multiple sclerosis.. Practitioner, 253(1721), 25 - 3.
    • Ciccarelli O, Toosy A, Freund P, Wheeler-Kingshott C, Miller D, Thompson AJ (2009). Neuronal mitochondrial dysfunction contributes to disability in multiple sclerosis: an in-vivo spinal cord imaging study.
    • Freund P, Wheeler-Kingshott C, Jackson J, Altman D, Miller D, Thompson AJ, Ciccarelli O (2009). Spinal cord diffusion tensor radial diffusivity predicts recovery after a cord relapse in multiple sclerosis.

    2008

    • Thompson AJ (2008). Multiple sclerosis-a global disorder and still poorly managed. The Lancet Neurology, 7(12), 1078 - 1079. doi:10.1016/S1474-4422(08)70246-1
    • McCrone P, Heslin M, Knapp M, Bull P, Thompson A (2008). Multiple Sclerosis in the UK Service Use, Costs, Quality of Life and Disability. PHARMACOECONOMICS, 26(10), 847 - 860.
    • Khaleeli Z, Altmann DR, Cercignani M, Ciccarelli O, Miller DH, Thompson AJ (2008). Magnetization transfer ratio in gray matter. A potential surrogate marker for progression in early primary progressive multiple sclerosis.. Archives of Neurology, 65(11), 1454 - 1459. doi:10.1001/archneur.65.11.1454
    • Ciccarelli O, Altmann D, McLean M, Wheeler-Kingshott CA, Wimpey K, Miller DH, Thompson AJ (2008). An investigation of repair mechanisms after spinal cord relapse in multiple sclerosis using magnetic resonance imaging.
    • Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH (2008). Gray matter atrophy is related to long-term disability in multiple sclerosis. Annals of Neurology, 64(3), 247 - 254. doi:10.1002/ana.21423
    • Swanton JK, Kryshani FT, Dalton C, Miszkiel KA, Altmann DR, Plant G, Chard DT, Thompson AJ, Miller DH (2008). Predicting disability in patients presenting with optic neuritis: the role of early magnetic resonance imaging parameters.
    • Anderson VM, Fisniku LK, Altmann D, Chard DT, Thompson AJ, Miller DH (2008). Reduced cerebellar grey matter volume is associated with cerebellar dysfunction in multiple sclerosis.
    • Altmann D, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos L, Molyneux P, Polman CH, Pozzilli C, Thompson AJ, Wagner K, Yousry T, Miller DH, EUSPMS MRI SubStudy Grp (2008). Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis.
    • Khaleeli Z, Ciccarelli O, Manfredonia F, Altmann D, Miller DH, Thompson AJ (2008). Spinal cord atrophy in early and established primary progressive multiple sclerosis: a two-year follow-up.
    • Giorgio A, Filippi M, Battaglini M, Rovaris M, Barkhof F, Korteweg T, Fazekas F, Enzinger C, Calabrese M, Dinacci D, Tedeschi G, Gass A, Montalban X, Rovira A, Miller D, Thompson AJ, De Stefano N (2008). The progression of brain atrophy is similar in drug-free MS sub-types: A longitudinal study of a large patient population.
    • Bonati U, Fisniku LK, Yiannakas M, Altmann D, Furby J, Thompson AJ, Miller DH (2008). Upper cervical cord atrophy reflects disease subtype and disability in patients with multiple sclerosis followed up 20 years from disease onset with a clinically isolated syndrome.
    • Jenkins T, Mancini L, Ciccarelli O, Toosy A, Altmann D, Chappell K, Plant G, Miller D, Thompson AJ (2008). Using structural and functional magnetic resonance imaging to explain visual loss at the onset of acute optic neuritis.
    • Rakusa M, Cano SJ, Porter B, Riazi A, Thompson A, Chataway J (2008). A predictive model to determine the effect of corticosteroids in treating individual patients with multiple sclerosis relapses.
    • Ciccarelli O, Catani M, Johansen-Berg H, Clark CA, Thompson A (2008). Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. The Lancet Neurology, 7(8), 715 - 727. doi:10.1016/S1474-4422(08)70163-7
    • Morley DP, Selai CE, Thompson AJ (2008). Preliminary validation of the self-report Barthel Index in people with Parkinson's disease.
    • Bosnell R, Wegner C, Kincses ZT, Korteweg T, Agosta F, Ciccarelli O, De Stefano N, Gass A, Hirsch J, Johansen-Berg H, Kappos L, Barkhof F, Mancini L, Manfredonia F, Marino S, Miller DH, Montalban X, Palace J, Rocca M, Enzinger C, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Whitcher B, Filippi M, Matthews PM (2008). Reproducibility of fMRI in the clinical setting: implications for trial designs. NeuroImage, 42(2), 603 - 610. doi:10.1016/j.neuroimage.2008.05.005
    • Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R, Hobart JC (2008). The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?. Health and Quality of Life Outcomes, 6, 58 - . doi:10.1186/1477-7525-6-58
    • Rocca M, Absinta M, Valsasina P, Ciccarelli O, Thompson AJ, Mancini L, Marino S, De Stefano N, Rovira A, Montalban X, Gass A, Kappos L, Wegner C, Enzinger C, Ropele S, Korteweg T, Barkhof F, Matthews PM, Filippi M (2008). Abnormal connectivity inside the motor network in patients with multiple sclerosis: a multicentre fMRI study.
    • Khaleeli Z, Ciccarelli O, Manfredonia F, Barkhof F, Brochet B, Cercignani M, Dousset V, Filippi M, Montalban X, Polman C, Rovaris M, Rovira A, Sastre-Garriga J, Vellinga M, Miller D, Thompson A (2008). Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study. Annals of Neurology, 63(6), 790 - 793. doi:10.1002/ana.21375
    • Bodini B, Khaleeli Z, Cercignani M, Miller DH, Thompson AJ, Ciccarelli O (2008). The relationship between brain NAWM and GM damage is localised to specific, clinically relevant areas in early primary progressive multiple sclerosis.
    • Rocca MA, Agosta F, Sormani MP, Fernando K, Tintore M, Korteweg T, Tortorella P, Miller DH, Thompson A, Rovira A, Montalban X, Polman C, Barkhof F, Filippi M (2008). A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal of Neurology, 255(5), 683 - 691. doi:10.1007/s00415-008-0776-z
    • Manson SC, Wegner C, Filippi M, Barkhof F, Beckmann C, Ciccarelli O, De Stefano N, Enzinger C, Fazekas F, Agosta F, Gass A, Hirsch J, Johansen-Berg H, Kappos L, Korteweg T, Polman C, Mancini L, Manfredonia F, Marino S, Miller DH, Montalban X, Palace J, Rocca M, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Frank JA, Matthews PM (2008). Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Experimental Brain Research, 187(1), 25 - 31. doi:10.1007/s00221-008-1276-1
    • Rovaris M, Judica E, Sastre-Garriga J, Rovira A, Sormani MP, Benedetti B, Korteweg T, De Stefano N, Khaleeli Z, Montalban X, Barkhof F, Miller DH, Polman C, Thompson AJ, Filippi M (2008). Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis, 14(4), 455 - 464. doi:10.1177/1352458507085129
    • Jenkins TM, Khaleeli Z, Thompson AJ (2008). Diagnosis and management of primary progressive multiple sclerosis. Minerva Medica, 99(2), 141 - 155.
    • Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS (2008). Ethics of placebo-controlled clinical trials in multiple sclerosis - A reassessment. Neurology, 70(13 Part 2), 1134 - 1140. doi:10.1212/01.wnl.0000306410.84794.4d
    • Farrell R, Anthony D, Clark D, Swanton J, Fisniku L, Khaleeli Z, Garson J, Thompson AJ, Miller DH, Giovannoni G (2008). Is multiple disease activity, as detected by gadolinium enhanced MRI, associated with virological and immunological evidence of EBV reactivation in peripheral blood?.
    • van der Linden FAH, Kragt JJ, van Bon M, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BMJ (2008). Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years. BMC Neurology, 8, 2 - . doi:10.1186/1471-2377-8-2
    • Wegner C, Filippi M, Korteweg T, Beckmann C, Ciccarelli O, De Stefano N, Enzinger C, Fazekas F, Agosta F, Gass A, Hirsch J, Johansen-Berg H, Kappos L, Barkhof F, Polman C, Mancini L, Manfredonia F, Marino S, Miller DH, Montalban X, Palace J, Rocca M, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Matthews PM (2008). Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. European Journal of Neurology, 15(2), 113 - 122. doi:10.1111/j.1468-1331.2007.02027.x
    • Seewann A, Enzinger C, Filippi M, Barkhof F, Rovira A, Gass A, Miller D, Montalban X, Thompson A, Yousry T, Tintore M, De Stefano N, Palace J, Rovaris M, Polman C, Fazekas F (2008). MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. Journal of Neurology, 255(1), 1 - 10. doi:10.1007/s00415-007-0754-x
    • Antel J, Carroll W, Thompson A (2008). Untitled. MULT SCLER, 14(9), 1153 - 1153. doi:10.1177/1352458508098093
    • Fisniku LK, Brex PA, Chard DT, Jackson J, Altmann D, Miszkiel KA, Thompson AJ, Miller D (2008). Changes in brain lesion load over 20 years and subsequent brain atrophy in clinically isolated syndrome patients.
    • Di Filippo M, Anderson VM, Altmann D, Swanton JK, Plant GT, Thompson AJ, Miller DH (2008). Early brain atrophy and lesion load measures relate to clinical status after six years in patients with clinically isolated syndromes.
    • Bodini B, Khaleeli Z, Cercignani M, Miller DH, Thompson AJ, Ciccarelli O (2008). Early corpus callosum damage predicts progression of disability over 3 years in primary progressive multiple sclerosis.
    • Khaleeli Z, Ciccarelli O, Miszkiel KA, Thompson AJ, Altmann D, Miller DH (2008). Gadolinium enhancing lesions decrease over time in early primary progressive multiple sclerosis.
    • Kolappan M, Connick P, Compston A, Thompson AJ, Chandran S, Miller D, NMR Res Unit (2008). Optic neuritis as a sentinel lesion to study neuroprotection and repair in a trial of autologous mesenchymal stem cells in multiple sclerosis.
    • Thompson AJ (2008). Rehabilitation of cognitive impairment.
    • Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintore M, Uitdehaag BM (2008). The search for responsive clinical endpoints in primary progressive multiple sclerosis.
    • Thompson AJ, Rompani P, Dua T, Douglas I, Battaglia M, Porter B (2008). WHO/MSIF: Atlas of MS: multiple sclerosis resources across the world.
    • Kerrison S, Laws S, Cane M, Thompson A (2008). The patient's experience of being a human subject.. J R Soc Med, 101(8), 416 - 422. doi:10.1258/jrsm.2007.070288
    • Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, Inglese M, Guttmann CRG, Horsfield MA, Filippi M (2008). MRI in multiple sclerosis: current status and future prospects. The Lancet Neurology, 7(7), 615 - 625. doi:10.1016/S1474-4422(08)70137-6
    • Farrell R, Antony D, Clark D, Swanton J, Fisniku L, Khaleeli Z, Thompson A, Miller DH, Giovannoni G (2008). Investigation of role of peripheral EBV reactivation in driving multiple sclerosis disease activity as measured by gadolinium enhanced MRI.
    • Fisniku LK, Gutierrez L, Brex PA, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH (2008). Changes in brain lesion load over 20 years and subsequent ventricular volumes in clinically isolated syndrome patients.
    • Kesselring J, Coenen M, Cieza A, Thompson A, Kostanjsek N, Stucki G (2008). Developing the ICF Core Sets for multiple sclerosis to specify functioning. MULT SCLER, 14(2), 252 - 254. doi:10.1177/1352458507082615
    • Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH (2008). Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain, 131(3), 808 - 817. doi:10.1093/brain/awm329
    • Rashid W, Hadjiprocopis A, Davies G, Griffin C, Chard D, Tiberio M, Altmann D, Wheeler-Kingshott C, Tozer D, Thompson A, Miller DH (2008). Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging. Journal of Neurology, 255(3), 390 - 397. doi:10.1007/s00415-008-0678-0
    • Farrell R, Kapoor R, Leary S, Rudge P, Thompson AJ, Miller DH, Giovannoni G (2008). Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Multiple Sclerosis, 14(2), 212 - 218. doi:10.1177/1352458507082066
    • Kragt JJ, Thompson AJ, Montalban X, Tintore M, Rio J, Polman CH, Uitdehaag BM (2008). Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology, 70(13 Pt 2), 1084 - 1091. doi:10.1212/01.wnl.0000288179.86056.e1
    • Costelloe L, Thompson A, Walsh C, Tubridy N, Hutchinson M (2008). Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. Journal of Neurology, Neurosurgery and Psychiatry, 79(11), 1245 - 1248. doi:10.1136/jnnp.2008.143586

    2007

    • Gorgoraptis N, Wheelet-Kingshott C, Jenkins T, Miller DH, Thompson AJ, Ciccarelli O (2007). A probabilistic tractography study of the cortico-spinal tract in patients with multiple sclerosis.
    • Rashid W, Davies GR, Chard DT, Griffin CM, Altmann DR, Thompson AJ, Miller DH (2007). Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Multiple Sclerosis, 13(2), 178 - 185. doi:10.1177/1352458506070758
    • Khaleeli Z, Sastre-Garriga J, Ciccarelli O, Miller DH, Thompson AJ (2007). Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 78(10), 1076 - 1082. doi:10.1136/jnnp.2006.107565
    • Fisniku L, Gutierrez L, Swanton J, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH (2007). Ventricular volume in a cohort of clinically isolated syndrome patients followed up 20 years after the onset of disease.
    • Cano SJ, Zajicek JP, Thompson AJ, Hobart JC (2007). Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon.
    • Fisniku LK, Brex PA, Miszkiel K, Altmann DR, Thompson AJ, Miller DH (2007). Disability and T2 MRI abnormalities: A 20 year follow-up of patients with relapse onset of multiple sclerosis.
    • Farrell R, Leary S, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G (2007). Evaluation of anti-interferon beta antibodies in subjects with multiple sclerosis attending the national hospital for neurology and neurosurgery, London.
    • Khaleeli Z, Cercignani M, Audoin B, Ciccarelli O, Miller DH, Thompson AJ (2007). Localised grey matter magnetisation transfer ratio changes contribute to disability in primary progressive multiple sclerosis.
    • Ciccarelli O, Wheeler-Kingshott C, McLean M, Wimpley K, Cercignani M, Miller DH, Thompson AJ (2007). Spinal cord diffusion imaging and spectroscopy to assess the impact of acute lesions in multiple sclerosis.
    • Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, Huerga E, Miszkiel KA, Plant GT, Polman C, Rovaris M, Thompson AJ, Montalban X, Miller DH (2007). MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study.. The Lancet Neurology, 6(8), 677 - 686. doi:10.1016/S1474-4422(07)70176-X
    • Audoin B, Davies G, Rashid W, Fisniku L, Thompson AJ, Miller DH (2007). Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Multiple Sclerosis, 13(4), 483 - 489. doi:10.1177/1352458506070450
    • Manfredonia F, Ciccarelli O, Khaleeli Z, Tozer DJ, Sastre-Garriga J, Miller DH, Thompson AJ (2007). Normal-appearing brain T1 relaxation time predicts disability in early primary progressive multiple sclerosis. Archives of Neurology, 64(3), 411 - 415.
    • Ward NS, Newton JM, Swayne OB, Lee L, Frackowiak RS, Thompson AJ, Greenwood RJ, Rothwell JC (2007). The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke.. European Journal of Neuroscience, 25(6), 1865 - 1873. doi:10.1111/j.1460-9568.2007.05434.x
    • Cano SJ, Thompson A, Bhatia K, Fitzpatrick R, Warner TT, Hobart JC (2007). Evidence-based guidelines for using the Short Form 36 in cervical dystonia.. Movement Disorders, 22(1), 122 - 127.
    • Wolinsky J, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, et al (2007). Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology, 61(1), 14 - 24.
    • Thompson AJ (2007). Promises, promises... Annals of Neurology, 61(1), 1 - 2. doi:10.1002/ana.21083
    • Leary SM, Thompson AJ (2007). Treatment for patients with primary progressive multiple sclerosis. In Cohen JA, Rudick RA (Ed.), Multiple sclerosis therapeutics (pp. 751 - 760). : informa healthcare.
    • Zarei M, Johansen-Berg H, Jenkinson M, Ciccarelli O, Thompson AJ, Matthews PM (2007). Two-dimensional population map of cortical connections in the human internal capsule. Journal of Magnetic Resonance Imaging, 25(1), 48 - 54. doi:10.1002/jmri.20810
    • Hobart JC, Cano SJ, Zajicek JP, Thompson AJ (2007). Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. The Lancet Neurology, 6(12), 1094 - 1105. doi:10.1016/S1474-4422(07)70290-9
    • Thompson AJ (2007). Measuring the outcomes in neurorehabilitation.
    • Thompson AJ (2007). Principles of neurorehabilitation and its application to chronic neurological disorders. Neurologia, 3(Suppl.7), 1 - 8.
    • Farrell R, Leary S, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G (2007). Neutralising antibodies to interferon beta are associated with loss of efficacy of treatment and reduced side effects.
    • van Ter Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BMJ (2007). Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact?.
    • Miller DH, MacManus D, Thompson AJ, Kappos L, Barkhof F, Polman CH, Wagner K, Sandbrink R, Beckmann K, Pozzilli C, Santana V, Barker GJ (2007). Slowing of cerebral atrophy after year 1 in a placebo-controlled trial of interferon beta 1b in secondary progressive multiple sclerosis.
    • Khaleeli Z, Cercignani M, Audoin B, Ciccarelli O, Miller DH, Thompson AJ (2007). Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability.. NeuroImage, 37(1), 253 - 261. doi:10.1016/j.neuroimage.2007.04.056
    • Trip SA, Schlottmann PG, Jones SJ, Li WY, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH (2007). Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis. Multiple Sclerosis, 13(7), 875 - 879. doi:10.1177/1352458507076952
    • Ciccarelli O, Wheeler-Kingshott CA, McLean MA, Cercignani M, Wimpey K, Miller DH, Thompson AJ (2007). Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis.. Brain, 130(8), 2220 - 2231. doi:10.1093/brain/awm152
    • Jenkins TM, Thompson AJ (2007). GPs have pivotal role in managing MS. The Practitioner, 251(1694), 37 - 46.
    • Davies GR, Hadjiprocopis A, Altmann DR, Chard DT, Griffin CM, Rashid W, Parker GJ, Tofts PS, Kapoor R, Thompson AJ, Miller DH (2007). Normal-appearing grey and white matter T-1 abnormality in early relapsing-remitting multiple sclerosis: a longitudinal study. Multiple Sclerosis, 13(2), 169 - 177. doi:10.1177/1352458506070726
    • Bodini B, Cercignani M, Wheeler-Kingshott C, Miller DH, Thompson AJ, Ciccarelli O (2007). Localised damage in normal appearing white matter of early PPMS contributes to disability: a tract-based spatial statistics study.

    2006

    • Kallmann BA, Spech E, Kroner A, Petzold A, Miller D, Thompson A, Giovannoni G, Rieckmann P (2006). Differences in TRADD expression indicated by array analysis discriminates between NIS disease subtypes.
    • Holland A, O'Connor RJ, Thompson AJ, Playford ED, Hobart JC (2006). Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions?. Journal of Neurology, 253(12), 1594 - 1602. doi:10.1007/s00415-006-0272-2
    • Cano SJ, O'Connor RJ, Thompson AJ, Hobart JC (2006). Exploring disability rating scale responsiveness II: Do more response options help?. Neurology, 67(11), 2056 - 2059. doi:10.1212/01.wnl.0000247664.97643.e8
    • Manfredonia F, Khaleeli Z, Ciccarelli O, Sastre-Garriga J, Tozer DJ, Miller DH, Thompson AJ (2006). A longitudinal study of T1 relaxation time in normal appearing white matter and grey matter in early primary progressive multiple sclerosis.
    • Kallmann B, Spech E, Kroner A, Petzold A, Obojes K, Miller DH, Thompson A, Giovannoni G, Rieckmann P (2006). Different TRADD expression discriminates between multiple sclerosis disease subtypes.
    • Zarei M, Johansen-Berg H, Smith S, Ciccarelli O, Thompson AJ, Matthews PM (2006). Functional anatomy of interhemispheric cortical connections in the human brain. Journal of Anatomy, 209(3), 311 - 320. doi:10.1111/j.1469-7580.2006.00615.x
    • van der Linden FAH, Kragt JI, Hobart JC, van Bon MA, Klein M, Thompson AJ, van der Ploeg HM, Uitdehaag BMJ, Polman CH (2006). Longitudinal proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life over a period of two years.
    • Fernando KTM, Chard DT, McLean MA, Swanton JK, Miszkiel KA, Gordon RM, Altmann DR, Plant GT, Thompson AJ, Miller DH (2006). Metabolite changes in the white matter 3 years after a clinically isolated syndrome suggestive of multiple sclerosis.
    • Trip SA, Schlottmann P, Jones S, Garway-Heath DF, Thompson A, Plant G, Miller DH (2006). Optic nerve head topography in optic neuritis.
    • Lanyon R, Dalton C, Swanton J, Plant GT, Thompson AJ, Miller DH (2006). Perceptions of MRI research in patients with clinically isolated syndromes.
    • Sepulcre J, Sastre-Garriga J, Cercignani M, Ingle GT, Miller DH, Thompson AJ (2006). Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Archives of Neurology, 63(8), 1175 - 1180.
    • Ciccarelli O, Toosy AT, Marsden JF, Wheeler-Kingshott CM, Miller DH, Matthews PM, Thompson AJ (2006). Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis. Journal of Neurology, 253(7), 882 - 891.
    • Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J, Thompson A (2006). Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial.. The Lancet Neurology, 5(7), 565 - 571. doi:10.1016/S1474-4422(06)70450-1
    • Ciccarelli O, Behrens TE, Altmann DR, Orrell RW, Howard RS, Johansen-Berg H, Miller DH, Matthews PM, Thompson AJ (2006). Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Brain, 129(7), 1859 - 1871.
    • Ramnani N, Beherns TEJ, Johansen-Berg H, Ritcher MC, Pinsk MA, Andersson JLR, Rudebeck P, Ciccarelli O, Richter W, Thompson AJ, Gross CG, Robson MD, Kastner S, Matthews PM (2006). The evolution of prefrontal inputs to the cortical-pontine system: diffusion imaging evidence from macaque monkeys and humans. Cerebral Cortex, 16(6), 811 - 818. doi:10.1093/cercor/bhj024
    • Ramdharry GM, Marsden JF, Day BL, Thompson AJ (2006). De-stabilising and training effects of foot orthoses in Multiple Sclerosis.. Multiple Sclerosis, 12(2), 219 - 226. doi:10.1191/135248506ms1266oa
    • Audoin B, Fernando KTM, Swanton JK, Thompson AJ, Plant GT, Miller DH (2006). Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain, 129(4), 1031 - 1039.
    • Rashid W, Davies GR, Chard DT, Griffin CM, Altmann DR, Gordon R, Kapoor R, Thompson AJ, Miller DH (2006). Upper cervical cord area in early relapsing-remitting multiple sclerosis: Cross-sectional study of factors influencing cord size. Journal of Magnetic Resonance Imaging, 23(4), 473 - 476.
    • Ward N, Newton JM, Swayne OB, Lee L, Thompson AJ, Greenwood RJ, Rothwell JC, Frackowiak RS (2006). Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain, 129(3), 809 - 819. doi:10.1093/brain/awl002
    • Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, McLean MA, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2006). Metabolite changes in early relapsing-remitting multiple sclerosis A two year follow-up study. Journal of Neurology, 253(2), 224 - 230.
    • Clark M, Playford ED, Thompson AJ (2006). Adolescent neurorehabilitation. DEV MED CHILD NEUROL, 48, 20 - 20.
    • Rashid W, Davies GR, Chard DT, Griffin CM, Altmann DR, Gordon R, Thompson AJ, Miller DH (2006). Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. Journal of Neurology, Neurosurgery and Psychiatry, 77(1), 51 - 55.
    • Hobart JC, Styles IM, Baron R, Thompson AJ, Andrich D (2006). Is it Rasch to compare thee on another scale?.
    • Ward NS, Brown MM, Thompson AJ, Frackowiak RSJ (2006). Longitudinal changes in cerebral response to proprioceptive input in individual patients after stroke: an FMRI study. Neurorehabilitation and Neural Repair, 20(3), 398 - 405.
    • Thompson AJ (2006). Neurological rehabilitation of multiple sclerosis.
    • Hobart JC, Zajicek JP, Thompson AJ (2006). Rating scales for neurological diseases: Lessons from Rasch analysis.
    • Thompson A (2006). Can we quantify the benefits of DMDs in multiple sclerosis?. The Lancet Neurology, 5(4), 290 - 291.
    • Audoin B, Davies GR, Finisku L, Chard DT, Thompson AJ, Miller DH (2006). Localization of grey matter atrophy in early RRMS : A longitudinal study. Journal of Neurology, 253(11), 1495 - 1501. doi:10.1007/s00415-006-0264-2
    • van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BMJ (2006). Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life. Journal of Neurology, Neurosurgery and Psychiatry, 77(10), 1157 - 1162.
    • Thompson AJ, Battaglia MA, Porter B, Dua T, Rompani PJ, Douglas I (2006). Atlas of multiple sclerosis, WHO/MSIF.
    • Bieniek M, Altmann DR, Davies GR, Ingle GT, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2006). Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 77(9), 1036 - 1039. doi:10.1136/jnnp.2006.094748
    • Drapier S, Swanton J, Altmann D, Fernando KTM, Dalton C, Thompson AJ, Plant G, Miller DH (2006). Increasing cord atrophy in clinical isolated syndrome group: a 5-year study.
    • Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant T, Miller DH (2006). Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. Journal of Neurology, Neurosurgery and Psychiatry, 77(9), 1070 - 1072.
    • Rovaris X, Judica E, Perego E, Benedetti B, Barkhof F, De Stefano N, Khaleeli Z, Korteweg T, Miller DH, Montalban X, Polman C, Rovira A, Sastre-Garriga J, Thompson AJ, Filippi M (2006). Multiparametric MRI assessment of brain and cord damage in primary progressive multiple sclerosis: a large-scale, multicentre study.
    • Trip SA, Schlottmann PG, Jones SJ, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH (2006). Quantification of optic nerve head topography in optic neuritis: a pilot study. British Journal of Ophthalmology, 90(9), 1128 - 1131.
    • Rejdak K, Leary SM, Petzold A, Stelmasiak Z, Thompson AJ, Miller DH, Giovannoni G (2006). Raised urinary neopterin excretion is associated with a better clinical outcome in PP-MS patients treated with interferon beta-1a.
    • Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, Miller DH (2006). Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 77(7), 830 - 833.
    • Karrenbauer VD, Leoni V, Lim ET, Giovannoni G, Ingle GT, Sastre-Garriga J, Thompson AJ, Rashid W, Davies G, Miller DH, Bjorkhem I, Masterman T (2006). Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clinical Neurology and Neurosurgery, 108(5), 456 - 460. doi:10.1016/j.clineuro.2005.07.010
    • Trip SA, Schlottmann PG, Jones SJ, Li WY, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH (2006). Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage., 31(1), 286 - 293.
    • Swanton JK, Fernando KTM, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, Miller DH (2006). Comparing the 2005 and 2001 McDonald criteria for the diagnosis of multiple sclerosis in clinically isolated syndrome patients.
    • Fisniku L, Brex P, Thompson AJ, Miller DH (2006). Disability after 20 years in a multiple sclerosis cohort followed from onset with a clinically isolated syndrome.
    • Rovaris M, Judica E, Benedetti B, Barkhof E, De Stefano N, Korteweg T, Miller D, Montalban X, Polman C, Rovira A, Sastre-Garriga J, Thompson A, Filippi M (2006). Multiparametric MRI assessment of brain and cord damage in primary progressive multiple sclerosis: a large-scale, multicentre study.
    • Fernando KTM, Chard DT, McLean MA, Altmann DR, Swanton JK, Gordon RM, Miszkiel KA, Plant GT, Thompson AJ, Miller DH (2006). Serial MR spectroscopy of the white matter in the first 3 years after the onset of a clinically isolated syndrome suggestive of multiple sclerosis.
    • Bieniek M, Altmann DR, Davies GR, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2006). Spinal cord atrophy separates early relapsing-remitting and primary progressive multiple sclerosis: a multimodal MRI study.
    • Trip SA, Wheeler-Kingshott C, Jones SJ, Li WY, Barker GJ, Thompson AJ, Plant GT, Miller DH (2006). Optic nerve diffusion tensor imaging in optic neuritis. NeuroImage, 30(2), 498 - 505.
    • Ramio-Torrenta L, Sastre-Garriga J, Ingle GT, Davies GR, Ameen V, Miller DH, Thompson AJ (2006). Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. Journal of Neurology, Neurosurgery and Psychiatry, 77(1), 40 - 45.
    • Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, Miller DH (2006). Evaluation of modified MRI criteria for multiple sclerosis in patients with clinically isolated syndromes.
    • Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ, Zajicek JP (2006). Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88).
    • Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ, Zajicek JP (2006). Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain, 129(1), 224 - 234.
    • Fernando KTM, Chard DT, McLean MA, Swanton JK, Gordon RM, Altmann DR, Dalton CM, Miszkiel KA, Plant GT, Thompson AJ, Miller DH (2006). Raised white matter myo-inositol after a clinically isolated syndrome is associated with the subsequent development of multiple sclerosis.
    • Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2006). CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia.. Neurology, 67(12), 2230 - 2232. doi:10.1212/01.wnl.0000249310.25427.f2

    2005

    • Camp SJ, Stevenson VL, Thompson AJ, Ingle GT, Miller DH, Borras C, Brochet B, Dousset V, Falautano M, Filippi M, Kalkers NF, Montalban X, Polman CH, Langdon DW (2005). A longitudinal study of cognition in primary progressive multiple sclerosis. Brain, 128(12), 2891 - 2898.
    • Sastre-Garriga J, Ingle GT, Chard DT, Ramio-Torrenta L, McLean MA, Miller DH, Thompson AJ (2005). Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Archives of Neurology, 62(4), 569 - 573.
    • Cook PA, Zhang H, Avants BB, Yushkevich P, Alexander DC, Gee JC, Ciccarelli O, Thompson AJ (2005). An automated approach to connectivity-based partitioning of brain structures. In (Ed.), Medical Image Computing and Computer-Assisted Intervention – MICCAI 2005 (pp. 164 - 171). : . doi:10.1007/11566465_21
    • Davies GR, Dalton CM, Fernando KTM, Yousry TA, Thompson AJ, Miller DH (2005). Deep grey matter atrophy in patients with clinically isolated syndromes suggestive of multiple sclerosis.
    • Hobart JC, Andrich D, Zajicek JP, Thompson AJ (2005). Developing rating scales for multiple sclerosis: lessons from Rasch analysis.
    • Ciccarelli O, Toosy AT, Marsden JF, Wheeler-Kingshott CM, Sahyoun C, Matthews PM, Miller DH, Thompson AJ (2005). Identifying brain regions for integrative sensorimotor processing with ankle movements. Experimental Brain Research, 166(1), 31 - 42.
    • Davies GR, Altmann DR, Hadjiprocopis A, Rashid W, Chard DT, Griffin CM, Tofts PS, Barker GJ, Kapoor R, Thompson AJ, Miller DH (2005). Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. Journal of Neurology, 252(9), 1037 - 1044. doi:10.1007/s00415-005-0808-x
    • Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ (2005). Is inflammation important in early PPMS? a longitudinal MRI study. Journal of Neurology, Neurosurgery and Psychiatry, 76(9), 1255 - 1258.
    • van der Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BMJ (2005). Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life.
    • Sastre-Garriga J, Sepulcre J, Cercignani M, Ingle GT, Miller DH, Thompson AJ (2005). Regional grey matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study.
    • Audoin B, Davies GR, Thompson AJ, Miller DH (2005). Voxel-based analysis of grey matter MTR images in early relapsing-remitting multiple sclerosis.
    • O'Connor RJ, Cano SJ, Ramio-Torrenta LR, Thompson AJ, Playford ED (2005). Factors influencing work retention for people with multiple sclerosis Cross-sectional studies using qualitative and quantitative methods. Journal of Neurology, 252(8), 892 - 896.
    • Ciccarelli O, Toosy AT, Hickman SJ, Parker GJM, Wheeler-Kingshott CAM, Miller DH, Thompson AJ (2005). Optic radiation changes after optic neuritis detected by tractography-based group mapping. Human Brain Mapping, 25(3), 308 - 316.
    • O'Connor RJ, Cano SJ, Thompson AJ, Playford ED (2005). The impact of inpatient neurorehabilitation on psychological well-being on discharge and at 3 month follow-up. Journal of Neurology, 252(7), 814 - 819.
    • Sastre-Garriga J, Galán-Cartañá I, Montalbán X, Thompson A (2005). [Neurorehabilitation in multiple sclerosis].. Neurologia, 20(5), 245 - 254.
    • Davies GR, Altmann DR, Rashid W, Chard DT, Griffin CM, Barker GJ, Kapoor R, Thompson AJ, Miller DH (2005). Emergence of thalamic magnetization transfer ratio abnormality in early relapsing-remitting multiple sclerosis. Multiple Sclerosis, 11(3), 276 - 281. doi:10.1191/1352458505ms1166oa
    • Swanton JK, Fernando K, Dalton C, Miszkiel KA, Thompson AJ, Plant GT, Miller DH (2005). Evaluation of modified MRI criteria for multiple sclerosis in patients with clinically isolated syndromes.
    • Sastre-Garriga J, Ingle GT, Chard DT, Cercignani M, Ramio-Torrenta L, Miller DH, Thompson AJ (2005). Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain, 128(6), 1454 - 1460.
    • Fernando KTM, Tozer DJ, Miszkiel KA, Gordon RM, Altmann DR, Swanton J, Dalton CM, Brex PA, Barker GJ, Plant GT, Thompson AJ, Miller DH (2005). Magnetisation transfer histogram abnormalities in clinically isolated syndromes suggestive of multiple sclerosis.
    • Thompson AJ (2005). Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. Current Opinion in Neurology, 18(3), 267 - 271.
    • Trip SA, Schlottmann PG, Jones SJ, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH (2005). Retinal nerve fibre layer thickness correlates with visual dysfunction following optic neuritis.
    • Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (2005). Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. The Lancet Neurology, 4(5), 281 - 288.
    • Leary SM, Porter B, Thompson AJ (2005). Multiple sclerosis: diagnosis and the management of acute relapses. Postgraduate Medical Journal, 81(955), 302 - 308.
    • Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2005). Gray and white matter volume changes in early RRMS - A 2-year longitudinal study. Neurology, 64(6), 1001 - 1007.
    • Polman CH, Kappos L, Dahlke F, Graf R, Beckmann K, Bogumil T, Pozzilli C, Thompson AJ (2005). Interferon beta-1b treatment does not induce autoantibodies. Neurology, 64(6), 996 - 1000.
    • Ward N, Swayne O, Newton J, Lee L, Thompson A, Greenwood R, Rothwell J, Frackowiak R (2005). Motor system activation after subcortical stroke is related to corfico-spinal tract integrity.
    • Cook PA, Zhang H, Avants BB, Yushkevich P, Alexander DC, Gee JC, Ciccarelli O, Thompson AJ (2005). An automated approach to connectivity-based partitioning of brain structures. Med Image Comput Assist Interv, 8(1), 164 - 171.
    • Johansen-Berg H, Behrens TEJ, Sillery E, Ciccarelli O, Thompson AJ, Smith SM, Matthews PM (2005). Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cerebral Cortex, 15(1), 31 - 39. doi:10.1093/cercor/bhh105
    • Sastre-Garriga J, Ingle GT, Rovaris M, Tellez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ (2005). Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.. Neurology, 65, 633 - 635.
    • Leary SM, Porter B, Thompson AJ (2005). Multiple sclerosis: diagnosis and the management of acute relapses. In Morris H (Ed.), Neurology update: reviews for continuing professional development (pp. 249 - 263). : Radcliffe Publishing.
    • Leary SM, Thompson AJ (2005). Primary progressive multiple sclerosis - Current and future treatment options. CNS Drugs, 19(5), 369 - 376.
    • Toosy AT, Hickman SJ, Miszkiel KA, Jones SJ, Plant GT, Altmann DR, Barker GJ, Miller DH, Thompson AJ (2005). Adaptive cortical plasticity in higher visual areas after acute optic neuritis. Annals of Neurology, 57(5), 622 - 633.
    • Khaleeli Z, Sastre-Garriga J, Tozer DJ, Cercignani M, Ingle GT, Miller DH, Thompson AJ (2005). Longitudinal changes in magnetisation transfer ratio in normal-appearing brain tissues of patients with early primary progressive multiple sclerosis.
    • Fernando KTM, Tozer DJ, Miszkiel KA, Gordon RM, Swanton JK, Dalton CM, Barker GJ, Plant GT, Thompson AJ, Miller DH (2005). Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain, 128(12), 2911 - 2925. doi:10.1093/brain/awh654
    • Hobart J, Styles L, Baron R, Thompson A, Andrich D (2005). Is it Rasch to compare thee on another scale?.
    • Sastre-Garriga J, Galan-Cartana I, Montalban X, Thompson A (2005). Neurorehabilitation in multiple sclerosis [Neurorrehabilitaci½n en esclerosis mœltiple]. Neurologia, 20(5), 245 - 254.
    • Fernando KTM, Chard DT, Altmann DR, McLean MA, Miszkiel KA, Gordon RM, Swanton J, Dalton CM, Brex PA, Plant GT, Thompson AJ, Miller DH (2005). Raised white matter myo-inositol in patients with clinically isolated syndromes is associated with the development of multiple sclerosis.
    • Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ (2005). Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. Journal of Neurology, Neurosurgery and Psychiatry, 76(12), 1664 - 1669.
    • Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005). Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria". Annals of Neurology, 58(6), 840 - 846.
    • Sormani MP, Bruzzi P, Beckmann K, Kappos L, Miller DH, Polman C, Pozzilli C, Thompson AJ, Wagner K, Filippi M (2005). The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. Journal of Neurology, 252(12), 1455 - 1458.
    • Rejdak K, Leary SM, Stelmasiak Z, Miller DH, Thompson AJ, Giovannoni G (2005). Urinary nitric oxide metabolites and neopterin as markers of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients.
    • Thompson AJ, Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Weinshenker BY, Wolinsky JS (2005). New criteria for the diagnosis of multiple sclerosis.
    • Hobart J, Riazi A, Thompson A, Styles I, Ingram W, Vickery J, Warner M, Fox P, Zajicek J (2005). Getting the measure of spasticity in MS: the multiple sclerosis spasticity scale.
    • Chataway J, Porter B, Hobart J, Heaney D, Riazi A, Thompson AJ (2005). Home or away? A randomised controlled trial of treating acute multiple sclerosis relapses with intravenous steroids.
    • Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH (2005). Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Annals of Neurology, 58(3), 383 - 391. doi:10.1002/ana.20575
    • Audoin B, Fernando KTM, Thompson AJ, Miller DH (2005). Selective morphological changes in the primary visual cortex of CIS patients with optic neuritis.
    • Fisniku L, Brex PA, Thompson AJ, Miller DH (2005). The relationship between the T2-MRI abnormalities in CIS patients and the long-term outcome in a 20 year follow-up: a preliminary report.
    • Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (2005). Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. The Lancet Neurology, 4(6), 341 - 348.
    • Trip SA, Schlottmann RG, Jones SJ, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH (2005). Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of atrophy.
    • Freeman JA, Hobart JC, Playford ED, Undy B, Thompson AJ (2005). Evaluating neurorehabilitation: lessons from routine data collection. Journal of Neurology, Neurosurgery and Psychiatry, 76(5), 723 - 728.
    • Thompson AJ, Jarrett L, Lockley L, Marsden J, Stevenson VL (2005). Clinical management of spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 76(4), 459 - 463.
    • Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ (2005). How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. Journal of Neurology, Neurosurgery and Psychiatry, 76(11), 1539 - 1543.

    2004

    • Cano SJ, Warner TT, Fitzpatrick R, Bhatia K, Thompson AJ, Hobart JC (2004). The cervical dystonia impact profile (CDIP-58): A new patient-based rating scale.
    • Chard DT, Griffin CM, Rashid W, Davies GR, Altmann DR, Kapoor R, Barker GJ, Thompson AJ, Miller DH (2004). Progressive grey matter atrophy in clinically early relapsing- remitting multiple sclerosis. Multiple Sclerosis, 10(4), 387 - 391.
    • Serrien DJ, Strens LH, Cassidy MJ, Thompson AJ, Brown P (2004). Functional significance of the ipsilateral hemisphere during movement of the affected hand after stroke. Experimental Neurology, 190(2), 425 - 432.
    • Hickman SJ, Toosy AT, Jones SJ, Altmann DR, Miszkiel KA, MacManus DG, Barker GJ, Plant GT, Thompson AJ, Miller DH (2004). A serial MRI study following optic nerve mean area in acute optic neuritis. Brain, 127(11), 2498 - 2505.
    • Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R, Hobart JC (2004). Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology, 63(9), 1629 - 1633.
    • Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H (2004). Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology, 63(10), 1779 - 1787.
    • Lim ET, Petzold A, Leary SM, Altmann DR, Keir G, Thompson EJ, Miller DH, Thompson AJ, Giovannoni G (2004). Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. Journal of Negative Results in Biomedicine, 3(1), 4 - .
    • Rashid W, Parkes LM, Ingle GT, Chard DT, Toosy AT, Altmann DR, Symms MR, Tofts PS, Thompson AJ, Miller DH (2004). Abnormalities of cerebral perfusion in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 75(9), 1288 - 1293. doi:10.1136/jnnp.2003.026021
    • Hoffman K, Thompson A, Langdon DW (2004). Anxiety, rather than depression, is the key to pain in MS.
    • Ciccarelli O, Toosy AT, Marsden JF, Miller DH, Thompson AJ (2004). Motor disability after recovery from transverse myelitis relates to brain functional changes.
    • Hoffman K, Thompson A, Langdon DW (2004). Pain and discomfort in multiple sclerosis; equally disruptive but in different areas.
    • Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2004). Patient-based outcomes of cervical dystonia: A review of rating scales. Movement Disorders, 19(9), 1054 - 1059.
    • Rejdak K, Leary SM, Nelissen I, Opdenakker G, Dubois B, Thompson AJ, Giovannoni G (2004). Urinary neopterin is a sensitive marker of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients. EUR J NEUROL, 11, 120 - 120.
    • Teare L, Vickery J, Fox P, Wright D, Sanders H, Thompson A, Zajicek J, UK MS Res Grp (2004). Cannabinoids in MS - Long-term results from the CAMS.
    • Zajicek J, Thompson A, Hobart J (2004). Clinical trials in multiple sclerosis - The importance of the outcome measure.
    • Strens LHA, Asselman P, Pogosyan A, Loukas C, Thompson AJ, Brown P (2004). Corticocortical coupling in chronic stroke - Its relevance to recovery. Neurology, 63(3), 475 - 484.
    • Rashid W, Hadjiprocopis A, Griffin CM, Chard DT, Davies GR, Altmann DR, Wheeler-Kingshott C, Thompson AJ, Miller DH (2004). Evidence of evolving normal appearing brain tissue diffusion tensor imaging abnormalities in early relapsing-remitting multiple sclerosis.
    • Davies GR, Altmann DR, Hadjiprocopis A, Rashid W, Chard DT, Griffin CMB, Kapoor R, Thompson AJ, Miller DH (2004). Evidence that normal appearing grey and white matter MTR abnormalities predate symptom onset in relapsing-remitting MS.
    • Zajicek J, Fox R, Teare L, Sanders H, Wright D, Vickery J, Ingram W, Reilly S, Nunn A, Thompson A (2004). Cannabinoids in multiple sclerosis (CAMS) study, follow-up data suggesting an effect on disease progression.
    • Zajicek J, Thompson A, Hobart J (2004). Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure.
    • Strens L, Asselman R, Pogosyan A, Loukas C, Thompson A, Brown P (2004). EEG-EEG connectivity changes after chronic stroke are correlated with functional recovery.
    • Fernando KT, McLean MA, Chard DT, MacManus DG, Dalton CM, Miszkiel KA, Gordon RM, Plant GT, Thompson AJ, Miller DH (2004). Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain, 127(6), 1361 - 1369. doi:10.1093/brain/awh153
    • Davies G, Rashid W, Chard D, Griffin C, Barker G, Thompson A, Miller D (2004). Emergence of thalamic MTR abnormality in minimally disabled early relapsing-remitting MS patients.
    • Spech E, Kallmann B, Kroner A, Petzold A, Miller D, Thompson A, Giovannoni G, Toyka K, Rieckmann P (2004). Gene expression analysis indicates distinct immune pattern in relapsing remitting (RR) and primary progressive (PP) MS disease type.
    • Ward N, Brown MM, Thompson AJ, Frackowiak RSJ (2004). The influence of time after stroke on brain activations during a motor task.. Annals of Neurology, 55(6), 829 - 834. doi:10.1002/ana.20099
    • Sastre-Gariga J, Ingle GT, Chard DT, Ramio-Torrenta LI, McLean MA, Miller DH, Thompson AJ (2004). Brain metabolite changes in the early clinical stages of primary progressive multiple sclerosis.
    • Hobart J, Cano S, O'Connor R, Kinos S, Heinzlef O, Roullet E, Polman C, Uitdehaag B, McGuigan C, Hutchinson M, Durastanti V, Pozzilli C, Porcel J, Sastre-Garriga J, Montalban X, Mansson E, Lexell J, Thompson A (2004). Clinical trials in neurology: Are rating scales stable across European countries?.
    • Ciccarelli O, Toosy AT, Marsden JF, Ingle GT, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2004). Cortical motor reorganisation in primary progressive multiple sclerosis.
    • O'Connor RJ, Cano SJ, Thompson AJ, Hobart JC (2004). Exploring rating scale responsiveness: does the total score reflect the sum of its parts?. Neurology, 62(10), 1842 - 1844.
    • Hobart J, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ (2004). Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technology Assessment, 8(9), 1 - 48.
    • Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ (2004). Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.. Health Technol Assess, 8(9), iii - 48.
    • Hickman SJ, Toosy AT, Jones SJ, Altmann DR, Miszkiel KA, MacManus DG, Barker GJ, Plant GT, Thompson AJ, Miller DH (2004). Serial magnetization transfer imaging in acute optic neuritis. Brain, 127(3), 692 - 700.
    • Ingle GT, Sastre-Garriga J, Ramio L, Miller DH, Thompson AJ (2004). Spinal cord atrophy in early primary progressive multiple sclerosis.
    • Leary SM, Thompson AJ (2004). The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 75(3), 508 - 509.
    • Toosy AT, Ciccarelli O, Hickman SJ, Parker GJ, Wheeler-Kingshott CAM, Miller DH, Thompson AJ (2004). The relationship between function and structure of the posterior visual pathways following optic neuritis.
    • Rashid W, Hadjiprocopis A, Griffin CM, Chard DT, Davies GR, Barker GJ, Tofts PS, Thompson AJ, Miller DH (2004). Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction. Multiple Sclerosis, 10(1), 9 - 15. doi:10.1191/1352458504ms985oa
    • Trip SA, Hickman SJ, Toosy AT, Jones SJ, MacManus DG, Barker GJ, Plant GT, Thompson AJ, Miller DH (2004). Optic nerve mean area and magnetization transfer ratio at two years following acute optic neuritis.
    • Stevenson VL, Ingle GT, Miller DH, Thompson AJ (2004). Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study. Multiple Sclerosis, 10(4), 398 - 401. doi:10.1191/1352458504ms1055oa
    • Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C (2004). European validation of a standardized clinical description of multiple sclerosis.. Journal of Neurology, 251(12), 1472 - 1480.
    • Hoffman K, Thompson A, Langdon DW (2004). Assessing pain in multiple sclerosis; a simple question is not enough.
    • Hoffman K, Thompson A, Langdon DW (2004). Cognitive bias towards pain and MS; mediated by coping styles.
    • Sastre-Garriga J, Ingle GT, Chard DT, Ramio-Torrenta L, Miller DH, Thompson AJ (2004). Grey and white matter atrophy in clinically early PPMS: one year follow-up study.
    • Liu C, Thompson AJ, Playford ED (2004). Patient dissatisfaction: Insights into the rehabilitation process. Journal of Neurology, 251(9), 1094 - 1097.
    • Ramio-Torrenta LI, Ingle G, Sastre-Garriga J, Davies GR, Miller DH, Thompson AJ (2004). Abnormalities in normal looking brain tissue are present in early primary progressive multiple sclerosis and correlate with disability: A magnetisation transfer imaging study.
    • Leary SM, Traboulsee A, Miller DH, Thompson AJ (2004). The effect of interferon-beta-1a on magnetisation transfer ratio in primary progressive multiple sclerosis.
    • Hickman SJ, Toosy AT, Miszkiel KA, Jones SJ, Altmann DR, MacManus DG, Plant GT, Thompson AJ, Miller DH (2004). Visual recovery following acute optic neuritis. A clinical, electrophysiological and magnetic resonance imaging study. Journal of Neurology, 251(8), 996 - 1005.
    • Davies GR, Ramio-Torrenta L, Hadjiprocopis A, Chard DT, Griffin CMB, Rashid W, Barker GJ, Kapoor R, Thompson AJ, Miller DH (2004). Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 75(7), 998 - 1002. doi:10.1136/jnnp.2003.021915
    • Miller DH, Leary SM, Thompson AJ (2004). Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis. Multiple Sclerosis, 10(Suppl 1), S56 - S57.
    • Thompson A (2004). Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Multiple Sclerosis, 10(Suppl 1), S2 - S7.
    • Garrard P, Farnham C, Thompson AJ, Playford ED (2004). Rehabilitation of the cancer patient: experience in a neurological unit. Neurorehabilitation and Neural Repair, 18(2), pp.76 - 79.
    • Garrard P, Farnham C, Thompson AJ, Playford ED (2004). Rehabilitation of the cancer patient: experience in a neurological unit.. Neurorehabil Neural Repair, 18(2), 76 - 79. doi:10.1177/0888439004266306
    • Edwards SGM, Thompson AJ, Playford ED (2004). Integrated care pathways: disease-specific or process-specific?. Clinical Medicine, 4(2), 132 - 135.
    • Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, Plant GT, Thompson AJ, Miller DH (2004). Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain, 127(5), 1101 - 1107. doi:10.1093/brain/awh126
    • Sastre-Garriga J, Ingle GT, Chard DT, Ramio-Torrenta L, Miller DH, Thompson AJ (2004). Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. NeuroImage, 22(1), 353 - 359. doi:10.1016/j.neuroimage.2004.02.008
    • Toosy AT, Ciccarelli O, Parker GJ, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2004). Characterizing function-structure relationships in the human visual system with functional MRI and diffusion tensor imaging. NeuroImage, 21(4), 1452 - 1463.
    • Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A (2004). Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. MULT SCLER, 10(1), 41 - 46. doi:10.1191/1352458504ms983oa
    • Riazi A, Thompson AJ, Hobart JC (2004). Self-efficacy predicts self-reported health status in multiple sclerosis. Multiple Sclerosis, 10(1), 61 - 66.
    • Sastre-Garriga J, Tintor , M R, A N, C RO, J T, A J M, X (2004). Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. Archives of Neurology, 61(2), 222 - 224.
    • Davies GR, Tozer DJ, Cercignani M, Ramani A, Dalton CM, Thompson AJ, Barker GJ, Tofts PS, Miller DH (2004). Estimation of the macromolecular proton fraction and bound pool T2 in multiple sclerosis. Multiple Sclerosis, 10(6), 607 - 613.

    2003

    • Dalton CM, Brex PA, Miszkiel KA, Fernando K, MacManus DG, Plant GT, Thompson AJ, Miller DH (2003). Spinal cord MRI in clinically isolated optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry, 74(11), 1577 - 1580.
    • Patti F, Ciancio MR, Cacopardo M, Reggio E, Fiorilla T, Palermo F, Reggio A, Thompson AJ (2003). Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients--a randomised controlled trial. Journal of Neurology, 250(7), 861 - 866.
    • Miller DH, Thompson AJ, Filippi M (2003). Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. Journal of Neurology, 250(12), 1407 - 1419.
    • Kappos L, Polman C, Thompson AJ, Duda P, Clanet M, Comi G, Hartung HP, Montalban X (2003). Towards a European Network for Multiple Sclerosis Trials (ENMST). Multiple Sclerosis, 9(6), 627 - 629.
    • Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet, 362(9395), 1517 - 1526. doi:10.1016/S0140-6736(03)14738-1
    • Ward N, Brown MM, Thompson AJ, Frackowiak RS (2003). Neural correlates of motor recovery after stroke: a longitudinal fMRI study.. Brain, 126(11), 2476 - 2496. doi:10.1093/brain/awg245
    • Ingle GT, Stevenson VL, Miller DH, Thompson AJ (2003). Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain, 126(11), 2528 - 2536.
    • Behrens TEJ, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CAM, Boulby PA, Barker GJ, Sillery EL, Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM (2003). Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nature Neuroscience, 6(7), 750 - 757. doi:10.1038/nn1075
    • Ward N, Brown MM, Thompson AJ, Frackowiak RSJ (2003). Neural correlates of outcome after stroke: a cross-sectional fMRI study. Brain, 126(6), 1430 - 1448. doi:10.1093/brain/awg145
    • Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, Peto V, Thompson AJ (2003). Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. Journal of Neurology, Neurosurgery and Psychiatry, 74(6), 710 - 714.
    • Dalton CM, Brex PA, Miszkiel KA, Fernando K, MacManus DG, Plant GT, Thompson AJ, Miller DH (2003). New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Annals of Neurology, 53(5), 673 - 676. doi:10.1002/ana.10580
    • Horsfield MA, Barker GJ, Barkhof F, Miller DH, Thompson AJ, Filippi M (2003). Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. Journal of Magnetic Resonance Imaging, 17(4), 389 - 397.
    • Ciccarelli O, Werring DJ, Barker GJ, Griffin CM, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2003). A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging. Evidence of Wallerian degeneration. Journal of Neurology, 250(3), 287 - 292.
    • Garrard P, Bradshaw D, Jager HR, Thompson AJ, Losseff N, Playford DT (2003). Cognitive dysfunction after isolated brain stem insult: An underdiagnosed cause of long term morbidity.
    • Inglese M, Van Waesberghe JH, Rovaris M, Beckmann K, Barkhof F, Hahn D, Kappos L, Miller DH, Polman C, Pozzilli C, Thompson AJ, Yousry TA, Wagner K, Comi G, Filippi M (2003). The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology, 60(5), 853 - 860.
    • Sastre-Garriga J, Tintore M, Rovira A, Grive E, Pericot I, Comabella M, Thompson AJ, Montalban X (2003). Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Multiple Sclerosis, 9(1), 39 - 43.
    • Ciccarelli O, Parker GJM, Toosy AT, Wheeler-Kingshott CAM, Barker GJ, Boulby PA, Miller DH, Thompson AJ (2003). From diffusion tractography to quantitative white matter tract measures: a reproducibility study. NeuroImage, 18(2), 348 - 359.
    • Leary SM, Thompson AJ (2003). Interferon beta-1a in primary progressive multiple sclerosis. Journal of the Neurological Sciences, 206(2), 215 - 216.
    • Toosy AT, Orrell RW, Werring DJ, Howard RS, King MD, Barker GJ, Miller DH, Thompson AJ (2003). Diffusion tensor imaging detects corticospinal tract involvement at multiple levels in ALS..
    • Toosy AT, Werring DJ, Orrell RW, Howard RS, King MD, Barker GJ, Miller , D H T, A J (2003). Diffusion tensor imaging detects corticospinal tract involvement at multiple levels in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 74(9), 1250 - 1257. doi:10.1136/jnnp.74.9.1250
    • Thompson AJ (2003). Neurological rehabilitation. In Fowler TJ, Scadding JW (Ed.), Clinical neurology (pp. 551 - 556). : Arnold.
    • (2003). Neurological rehabilitation of Parkinson's Disease.
    • Davies GR, Ramani A, Dalton CM, Tozer DJ, Wheeler-Kingshott CAM, Barker GJ, Thompson AJ, Miller DH, Tofts PS (2003). Preliminary magnetic resonance study of the macromolecular proton fraction in white matter: a potential marker of myelin?. Multiple Sclerosis, 9(3), 246 - 249.
    • Freeman JA, Thompson AJ (2003). Rehabilitation in multiple sclerosis. In (Ed.), Multiple sclerosis 2 (pp. 317 - 328). : Butterworth Heinemann.
    • Thompson AJ, Hesse S (2003). Rehabilitation of motor function. In Brandt T (Ed.), Neurological disorders: course and treatment (pp. 1185 - 1197). : Academic Press.
    • Rashid W, Hadjiprocopis A, Griffin CM, Chard DT, Davies GR, Altmann DR, Barker GJ, Thompson AJ, Miller DH (2003). Brain tissue diffusion abnormalities may occur early in relapsing-remitting multiple sclerosis.
    • Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D (2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 126(10), 2191 - 2202. doi:10.1093/brain/awg224
    • Davies GR, Hadjiprocopis A, Rashid W, Griffin C, Chard D, Barker G, Tofts P, Kapoor R, Thompson AJ, Miller DH (2003). Evidence for progressive normal appearing grey and white matter MTR abnormality in early relapsing-remitting multiple sclerosis: A 2 year follow up study.
    • Liu C, Playford ED, Thompson AJ (2003). Is inpatient rehabilitation useful in relapsing-remitting multiple sclerosis?.
    • Chard DT, Griffin CM, Rashid W, Davies GR, Altmann DR, Kapoor R, Barker GJ, Thompson AJ, Miller DH (2003). Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis.
    • Hickman SJ, Coulon O, Parker GJM, Barker GJ, Stevenson VL, Chard DT, Arridge SR, Thompson AJ, Miller DH (2003). Application of a B-spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three-dimensional MR images. Journal of Magnetic Resonance Imaging, 18(3), 368 - 371. doi:10.1002/jmri.10354
    • Simon JH, Thompson AJ (2003). Is multiple sclerosis still a clinical diagnosis?. Neurology, 61(5), 596 - 597.
    • Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ (2003). Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta 1a. Journal of Neurology, 250(9), 1037 - 1043.
    • Giovannoni G, Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, Miller DH (2003). Beta-interferon in multiple sclerosis: An assessment of the ABN stopping criteria in clinical practice.
    • Edwards SGM, Playford ED, Hobart JC, Thompson AJ (2003). Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation.
    • Ciccarelli O, Toosy AT, Parker GJM, Wheeler-Kingshott CAM, Barker GJ, Miller DH, Thompson AJ (2003). Diffusion tractography based group mapping of major white-matter pathways in the human brain. NeuroImage, 19(4), 1545 - 1555. doi:10.1016/S1053-8119(03)00190-3
    • Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G (2003). Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. Journal of Neurology, Neurosurgery and Psychiatry, 74(7), 946 - 949. doi:10.1136/jnnp.74.7.946
    • Chard DT, Brex PA, Ciccarelli O, Griffin CM, Parker GJM, Dalton C, Altmann DR, Thompson AJ, Miller DH (2003). The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. Journal of Neurology, Neurosurgery and Psychiatry, 74(11), 1551 - 1554.
    • Baker D, Pryce G, Giovannoni G, Thompson AJ (2003). The therapeutic potential of cannabis. The Lancet Neurology, 2(5), 291 - 298.
    • Zoukos Y, Thomaides TN, Kidd D, Cuzner ML, Thompson A (2003). Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. Journal of Neurology, Neurosurgery and Psychiatry, 74(2), 197 - 202.
    • Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ (2003). Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Multiple Sclerosis, 9(4), 411 - 419.
    • Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ (2003). Interferon beta-1a in primary progressive MS - An exploratory, randomized, controlled trial. Neurology, 60(1), 44 - 51.
    • Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ (2003). Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31 - 36.
    • Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau J, Miller D (2003). Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology, 60(1), 37 - 43.
    • McDonald WI, Fazekas F, Thompson AJ (2003). The diagnosis of multiple sclerosis. In (Ed.), Multiple sclerosis 2 (pp. 1 - 11). : Butterworth Heinemann.
    • Dehmeshki J, Chard DT, Leary SM, Watt HC, Silver NC, Tofts PS, Thompson AJ, Miller DH (2003). The normal appearing grey matter in primary progressive multiple sclerosis - A magnetisation transfer imaging study. Journal of Neurology, 250(1), 67 - 74.
    • Leary SM, Thompson AJ (2003). Treatment for patients with primary progressive multiple sclerosis. In Cohen JA, Rudick RA, McFarland H (Ed.), Multiple sclerosis therapeutics (pp. 589 - 598). : Martin Dunitz.
    • Thompson AJ (2003). Treatment of progressive multiple sclerosis. In (Ed.), Multiple sclerosis 2 (pp. 341 - 359). : Butterworth Heinemann.
    • Giovannoni G, Polman CH, Petkau J, Thompson AJ, Dahlke F, Kappos L (2003). Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b: discussion. Neurology, 61(7), 1025 - .
    • Ingle GT, Stevenson VL, Leary SM, Miller DH, Thompson AJ (2003). A 5 year longitudinal MRI study of primary progressive multiple sclerosis.
    • Toosy AT, Hickman SJ, Plant GT, Barker GJ, Miller DH, Thompson AJ (2003). A functional magnetic resonance imaging study of the longitudinal response to photic stimulation following acute optic neuritis.
    • Porter B, Keenan E, Record E, Thompson AJ (2003). Diagnosis of MS: a comparison of three different clinical settings. Multiple Sclerosis, 9(5), 431 - 439.
    • Liu C, Playford ED, Thompson AJ (2003). Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?. Journal of Neurology, 250(10), 1214 - 1218.
    • Sastre-Garriga J, Ingle GT, Ramio L, Miller DH, Thompson AJ (2003). Inflammation in early primary progressive multiple sclerosis.
    • Riazi A, Hobart JC, Fitzpatrick R, Freeman JA, Thompson AJ (2003). Socio-demographic variables are limited predictors of health status in multiple sclerosis. Journal of Neurology, 250(9), 1088 - 1093.
    • Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, Barkhof F (2003). Spinal-cord MRI in multiple sclerosis. The Lancet Neurology, 2(9), 555 - 562.
    • Polman CH, Kappos L, Petkau J, Thompson A (2003). Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J NEUROL NEUROSUR PS, 74(8), 1162 - 1162.
    • Traboulsee A, Dehmeshki J, Peters KR, Griffin CM, Brex PA, Silver N, Ciccarelli O, Chard DT, Barker GJ, Thompson AJ, Miller D (2003). Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Multiple Sclerosis, 9(6), 566 - 573. doi:10.1191/1352458503ms958oa

    2002

    • Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, O'Riordan JI, Plant GT, Thompson AJ, Miller DH (2002). Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73(2), 141 - 147.
    • Miller DH, Thompson AJ (2002). The diagnosis and management of multiple sclerosis. In Asbury AK, McKhann GM, McDonald WI, Goadsby PJ, McArthur JC (Ed.), Diseases of the nervous system: clinical neuroscience and therapeutic principles (pp. 1620 - 1632). : Cambridge University Press.
    • Chard DT, Parker GJM, Griffin CMB, Thompson AJ, Miller DH (2002). The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. Journal of Magnetic Resonance Imaging, 15(3), 259 - 267.
    • Ingle GT, Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Thompson AJ (2002). Two-year follow-up study of primary and transitional progressive multiple sclerosis. Multiple Sclerosis, 8(2), 108 - 114.
    • Hobart J, Riazi A, Lamping D, Fitzpatrick R, Thompson AJ (2002). Evaluating the use of B-INTERFERON in the UK: From whose perspective?. J NEUROL NEUROSUR PS, 73(2), 227 - 227.
    • Mann CL, Davies MB, Stevenson VL, Leary SM, Boggild MD, Ko Ko C, Jones PW, Fryer AA, Strange RC, Thompson AJ, Hawkins CP (2002). Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. Journal of Neuroimmunology, 129(1-2), 197 - 204. doi:10.1016/S0165-5728(02)00181-9
    • Chard DT, Brex PA, Ciccarelli O, Griffin CMB, Dalton C, Thompson AJ, Miller DH (2002). The predictive value of brain lesion load in determining brain atrophy in multiple sclerosis: 14 year follow up data following first presentation with a clinically isolated syndrome. J NEUROL NEUROSUR PS, 73(2), 214 - 214.
    • Davies GR, Chard DT, Griffin CMB, Rashid W, Thompson AJ, Miller DH (2002). Triple dose gadolinium enhanced MRI of the brain and spinal cord in early relapsing remitting multiple sclerosis is predictive of future relapses. J NEUROL NEUROSUR PS, 73(2), 226 - 226.
    • Dalton CM, Brex PA, Miszkiel KA, Plant GT, Hickman SJ, MacManus DG, Thompson AJ, Miller DH (2002). Validation of the McDonald criteria in patients with clinically isolated syndromes. J NEUROL NEUROSUR PS, 73(2), 214 - 214.
    • Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, Thompson AJ, Miller DH (2002). Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Annals of Neurology, 52(1), 47 - 53. doi:10.1002/ana.10240
    • Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002). A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. New England Journal of Medicine, 346(3), 158 - 164. doi:10.1056/NEJMoa011341
    • Thompson AJ, Baker D (2002). Cannabinoids in MS: potentially useful but not just yet!. Neurology, 58(9), 1323 - 1324.
    • Ingle GT, Thompson AJ, Miller DH (2002). Conventional MRI. In Filippi M, Comi G (Ed.), Primary progressive multiple sclerosis (pp. 63 - 76). : Springer-Verlag.
    • Thompson AJ (2002). Developing clinical outcome measures in multiple sclerosis: an evolving process. Multiple Sclerosis, 8(5), 357 - 358.
    • Ciccarelli O, Brex PA, Thompson AJ, Miller DH (2002). Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. Journal of Neurology, 249(1), 18 - 24.
    • Toosy AT, Werring DJ, Bullmore ET, Plant GT, Barker GJ, Miller DH, Thompson AJ (2002). Functional magnetic resonance imaging of the cortical response to photic stimulation in humans following optic neuritis recovery. Neuroscience Letters, 330(3), 255 - 259.
    • Playford ED, Sachs R, Thompson AJ (2002). Integrated care pathways: outcome from inpatient rehabilitation following nontraumatic spinal cord lesion. Clinical Rehabilitation, 16(3), 269 - 275.
    • Ingle GT, Thompson AJ, Miller DH (2002). Magnetic resonance imaging in primary progressive multiple sclerosis. Journal of Rehabilitation Research and Development, 39(2), 261 - 271.
    • Jarrett L, Nandi P, Thompson AJ (2002). Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73(6), 705 - 709.
    • Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ (2002). Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain, 125(8), 1676 - 1695.
    • Hobart JC, Williams LS, Moran K, Thompson AJ (2002). Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke, 33(5), 1348 - 1356.
    • Kapeller P, Brex PA, Chard DT, Dalton C, Griffin CM, McLean MA, Parker GJM, Thompson AJ, Miller DH (2002). Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis, 8(3), 207 - 210.
    • Griffin CM, Dehmeshki J, Chard DT, Parker GJM, Barker GJ, Thompson AJ, Miller DH (2002). T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. Multiple Sclerosis, 8(3), 211 - 216.
    • Griffin CM, Chard DT, Parker GJM, Barker GJ, Thompson AJ, Miller DH (2002). The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. Journal of Neurology, 249(2), 193 - 199.
    • Montalban X, Thompson AJ (2002). Workshop on primary progressive multiple sclerosis: meeting summary. Multiple Sclerosis, 8(2), 177 - 178.
    • Chard DT, Griffin CM, Parker GJM, Kapoor R, Thompson AJ, Miller DH (2002). Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain, 125(2), 327 - 337. doi:10.1093/brain/awf025
    • Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH (2002). Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain, 125(10), 2342 - 2352. doi:10.1093/brain/awf240
    • Ingle GT, Stevenson VL, Leary SM, Miller DH, Thompson AJ (2002). A 5 year longitudinal MRI study of ventricular volume in primary progressive multiple sclerosis. J NEUROL NEUROSUR PS, 73(2), 217 - 217.
    • Garrard P, Bradshaw D, Jager H, Thompson A, Losseff N, Playford D (2002). Cognitive dysfunction after isolated brain stem insult. An underdiagnosed cause of long term morbidity. Journal of Neurology, Neurosurgery and Psychiatry, 73(2), pp.191 - 194.
    • Edwards SG, Playford ED, Hobart JC, Thompson AJ (2002). Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation. BMJ (Clinical Research Ed.), 324(7352), 1493 - 1493. doi:10.1136/bmj.324.7352.1493
    • Edwards SG, Thompson AJ, Losseff N, Playford ED (2002). Shortening inpatient stay for stroke. The Lancet, 359(9324), 2205 - 2205. doi:10.1016/S0140-6736(02)09082-7
    • Hobart J, Thompson AJ (2002). Measurement of neurological outcomes. In Asbury AK, McKhann GM, McDonald WI, Goadsby PJ, McArthur JC (Ed.), Diseases of the nervous system: clinical neuroscience and therapeutic principles (pp. 105 - 117). : Cambridge University Press.
    • Stevenson VL, Smith SM, Matthews PM, Miller DH, Thompson AJ (2002). Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. Journal of Neurology, 249(2), 171 - 177.
    • Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ (2002). Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 73(6), 701 - 704.
    • Thompson AJ (2002). Progress in neurorehabilitation in multiple sclerosis. Current Opinion in Neurology, 15(3), 267 - 270.

    2001

    • Griffin CM, Chard DT, Ciccarelli O, Kapoor R, Barker GJ, Thompson AJ, Miller DH (2001). Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. Multiple Sclerosis, 7(5), 290 - 297. doi:10.1177/135245850100700504
    • Werring DJ, Clark CA, Droogan AG, Barker GJ, Miller DH, Thompson AJ (2001). Water diffusion is elevated in widespread regions of normal- appearing white matter in multiple sclerosis and correlates with diffusion in focal lesions. Multiple Sclerosis, 7(2), 83 - 89.
    • Miller DH, Thompson AJ, Kappos L (2001). MRI and assessment of treatment in multiple sclerosis. BRAIN, 124, 1052 - 1053.
    • Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A (2001). The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain, 124(5), 962 - 973. doi:10.1093/brain/124.5.962
    • Hickman S, Coulon O, Parker GJ, Barker GJ, Stevenson VL, Chard DT, Arridge SR, Thompson AJ, Miller DH (2001). Cervical spinal cord volume estimation using an active surface method: a amgnetic resonance imaging study in multiple sclerosis.
    • Freeman JA, Hobart JC, Thompson AJ (2001). Does adding MS-specific items to a generic measure (the SF-36) improve measurement?. Neurology, 57(1), 68 - 74.
    • Thompson AJ (2001). Drug treatment of neurological disability. In Edwards S (Ed.), Neurological physiotherapy: a problem solving approach (pp. 155 - 168). : Churchill Livingstone.
    • Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, Dahlke F, Kappos L, Polman C, Pozzilli C (2001). Interferon-beta 1b in the treatment of secondary progressive MS - Impact on quality of life. Neurology, 57(10), 1870 - 1875.
    • Brex PA, Leary SM, Plant GT, Thompson AJ, Miller DH (2001). Magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis. American Journal of Neuroradiology, 22(5), 947 - 951.
    • Brex PA, Leary SM, O'Riordan JI, Miszkiel KA, Plant GT, Thompson AJ, Miller DH (2001). Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 70(4), 544 - 547.
    • Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH (2001). Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Multiple Sclerosis, 7(2), 75 - 82.
    • McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology, 50(1), 121 - 127.
    • Losseff NA, Miller DH, Kidd D, Thompson AJ (2001). The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis: preliminary results. Multiple Sclerosis, 7(1), 23 - 25.
    • Hobart J, Freeman J, Lamping D, Fitzpatrick R, Thompson A (2001). The SF-36 in multiple sclerosis: why basic assumptions must be tested. Journal of Neurology, Neurosurgery and Psychiatry, 71(3), 363 - 370.
    • Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2001). Relation between serial MRI and the development of disability in patients with clinically isolated syndromes suggestive of multiple sclerosis. J NEUROL NEUROSUR PS, 71(3), 423 - 423.
    • Barkhof F, Van Waesberghe JHTM, Filippi M, Yousry T, Miller DH, Hahn D, Thompson AJ, Kappos L, Brex P, Pozzilli C, Polman CH (2001). T-1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain, 124(7), 1396 - 1402. doi:10.1093/brain/124.7.1396
    • Ciccarelli O, Werring DJ, Wheeler-Kingshott CAM, Barker GJ, Parker GJM, Thompson AJ, Miller DH (2001). Investigation of MS normal-appearing brain using diffusion tenser MRI with clinical correlations. Neurology, 56(7), 926 - 933.
    • Kapeller P, McLean MA, Griffin CM, Chard D, Parker GJM, Barker GJ, Thompson AJ, Miller DH (2001). Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. Journal of Neurology, 248(2), 131 - 138. doi:10.1007/s004150170248
    • Silver NC, Good CD, Sormani MP, MacManus DG, Thompson AJ, Filippi M, Miller DH (2001). A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. Journal of Neurology, 248(3), 215 - 224.
    • Camp SJ, Thompson AJ, Langdon DW (2001). A new test of memory for multiple sclerosis I. Format development and stimuli design. Multiple Sclerosis, 7(4), 255 - 262.
    • Brex PA, Miszkiel KA, O'Riordan JI, Plant GT, Moseley IF, Thompson AJ, Miller DH (2001). Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. Journal of Neurology, Neurosurgery and Psychiatry, 70(3), 390 - 393.
    • Hobart JC, Thompson AJ (2001). Assessment measures and clinical scales. In Guiloff RJ (Ed.), Clinical trials in neurology (pp. 17 - 28). : Springer Verlag.
    • Toosy AT, Werring DJ, Plant GT, Bullmore ET, Miller DH, Thompson AJ (2001). Asymmetrical activation of human visual cortex demonstrated by functional MRI with monocular stimulation. NeuroImage, 14(3), 632 - 641.
    • Freeman JA, Thompson AJ (2001). Building an evidence base for multiple sclerosis management: support for physiotherapy. Journal of Neurology, Neurosurgery and Psychiatry, 70(2), 147 - 148.
    • Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH (2001). Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology, 57(12), 2191 - 2197.
    • van der Putten JMF, Stevenson VL, Playford ED, Thompson AJ (2001). Factors affecting functional outcome in patients with nontraumatic spinal cord lesions after inpatient rehabilitation. Neurorehabilitation and Neural Repair, 15(2), 99 - 104.
    • Giovannoni G, Thompson AJ, Miller DH, Thompson EJ (2001). Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology, 57(4), 676 - 681.
    • Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F (2001). Final analysis of the European multicenter trial on IFN beta-1b in secondary-progressive MS. Neurology, 57(11), 1969 - 1975.
    • Dehmeshki J, Silver NC, Leary SM, Tofts PS, Thompson AJ, Miller DH (2001). Magnetisation transfer ratio histogram analysis of primary progressive and other multiple sclerosis subgroups. Journal of the Neurological Sciences, 185(1), 11 - 17.
    • Jarrett L, Leary SM, Porter B, Richardson D, Rosso T, Powell M, Thompson AJ (2001). Managing spasticity in people with multiple sclerosis: a goal-oriented approach to intrathecal baclofen therapy. International Journal of MS Care, 3(4), - .
    • Polman CH, Thompson AJ, Murray TJ, McDonald WI (2001). Multiple sclerosis: the guide to treatment and management.
    • Thompson AJ, Playford ED (2001). Rehabilitation for patients with Parkinson's disease. The Lancet, 357(9254), 410 - 411.
    • Giovannoni G, Miller DH, Losseff NA, Sailer M, Lewellyn-Smith N, Thompson AJ, Thompson EJ (2001). Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. Journal of Neurology, 248(6), 487 - 495.
    • Thompson AJ (2001). Symptomatic management and rehabilitation in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 71(Suppl.), II22 - II27.
    • Thompson AJ (2001). Symptomotic treatment and rehabilitation. In Polman CH, Thompson AJ, Murray TJ, McDonald WI (Ed.), Multiple sclerosis: the guide to treatment and management (pp. 43 - 78). : Demos.
    • Losseff NA, Wang L, Miller DH, Thompson AJ (2001). T1 hypointensity of the spinal cord in multiple sclerosis. Journal of Neurology, 248(6), 517 - 521.
    • Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH (2001). T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 months follow-up study. European Journal of Neurology, 8(1), 37 - 42.
    • Willison HJ, O'Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, Fuhr P, Ford H, Hahn A, Renaud S, Katifi HA, Ponsford S, Reuber M, Steck A, Sutton I, Schady W, Thomas PK, Thompson AJ, Vallat JM, Winer J (2001). The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain, 124(10), 1968 - 1977.
    • Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA, Hahn D, Rolland Y, Salonen O, Pozzilli C, Polman CH, Thompson AJ, Kappos L, Miller DH (2001). The effect of IFN beta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology, 57(12), 2185 - 2190.
    • Hobart JC, Thompson AJ (2001). The five item Barthel index. Journal of Neurology, Neurosurgery and Psychiatry, 71(2), 225 - 230.
    • Hobart JC, Lamping DL, Freeman JA, Langdon DW, McLellan DL, Greenwood RJ, Thompson AJ (2001). Evidence-based measurement: which disability scale for neurologic rehabilitation?. Neurology, 57(4), 639 - 644.

    2000

    • Lazeron RHC, Langdon DW, Filippi M, Van Waesberghe JHTM, Stevenson VL, Boringa JBS, Origgi D, Thompson AJ, Falautano M, Polman CH, Barkhof F (2000). Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. Multiple Sclerosis, 6(4), 280 - 285.
    • Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, Harvey RJ, Rossor MN, Miller DH, Thompson AJ (2000). Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology, 54(4), 807 - 812.
    • Werring DJ, Bullmore ET, Toosy AT, Miller DH, Barker GJ, MacManus DG, Brammer MJ, Giampietro VP, Brusa A, Brex PA, Moseley IF, Plant GT, McDonald WI, Thompson AJ (2000). Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 68(4), 441 - 449.
    • Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ, MacManus DG, Thompson AJ, Miller DH (2000). The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain, 123, 1667 - 1676.
    • Richardson D, Greenwood RJ, Sheean G, Thompson AJ, Edwards S (2000). Treatment of focal spasticity with botulinum toxin: effect on the "positive support reaction". Physiotherapy Research International, 5(1), 62 - 70.
    • Thompson AJ (2000). The effectiveness of neurological rehabilitation in multiple sclerosis. Journal of Rehabilitation Research and Development, 37(4), 455 - 461.
    • Stevenson VL, Parker GJM, Barker GJ, Birnie K, Tofts PS, Miller DH, Thompson AJ (2000). Variations in T1 and T2 relaxation times of normal appearing white matter and lesions in multiple sclerosis. Journal of the Neurological Sciences, 178(2), 81 - 87.
    • Foong J, Rozewicz L, Chong WK, Thompson AJ, Miller DH, Ron MA (2000). A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis. Journal of Neurology, 247(2), 97 - 101.
    • Kersten P, McLellan DL, Gross-Paju K, Grigoriadis N, Bencivenga R, Beneton C, Charlier M, Ketelaer P, Thompson AJ (2000). A questionnaire assessment of unmet needs for rehabilitation services and resources for people with multiple sclerosis: results of a pilot survey in five European countries. Clinical Rehabilitation, 14(1), 42 - 49.
    • Nicholas R, Playford ED, Thompson AJ (2000). A retrospective analysis of outcome in severe Guillain-Barre syndrome following combined neurological and rehabilitation management. Disability and Rehabilitation, 22(10), 451 - 455.
    • Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Dousset V, Filippi M, Hintzen R, Montalban X, Polman CH, Rovira A, De Sa J, Thompson AJ (2000). One year follow up study of primary and transitional progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 68(6), 713 - 718.
    • Dobkin BH, Thompson AJ (2000). Principles of neurological rehabilitation. In Bradley WG, Daroff RB, Fenichel GM, Marsden CD (Ed.), Neurology in clinical practice: volume 1. Principles of diagnosis and management (pp. 959 - 1005). : Butterworth Heinemann.
    • Langdon DW, Thompson AJ (2000). Relation of impairment to everyday competence in visual disorientation syndrome: evidence from a single case study. Archives of Physical Medicine and Rehabilitation, 81(5), 686 - 691.
    • Freeman JA, Thompson AJ (2000). Community services in multiple sclerosis: still a matter of chance. Journal of Neurology, Neurosurgery and Psychiatry, 69(6), 728 - 732.
    • Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff NA, Barker GJ, Thompson AJ, Miller DH (2000). The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain, 123(11), 2256 - 2263.
    • Weatherby SJM, Mann CLA, Fryer AA, Strange RC, Hawkins CP, Stevenson VL, Leary SM, Thompson AJ (2000). No association between the APOE epsilon 4 allele and outcome and susceptibility in primary progressive multiple sclerosis. J NEUROL NEUROSUR PS, 68(4), 532 - 532.
    • Leary SM, Brex PA, MacManus DG, Parker GJM, Barker GJ, Miller DH, Thompson AJ (2000). A H-1 magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Magnetic Resonance Imaging, 18(4), 455 - 459.
    • Freeman JA, Hobart JC, Langdon DW, Thompson AJ (2000). Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 68(2), 150 - 156.
    • Leary SM, Thompson AJ (2000). Current management of multiple sclerosis. International Journal of Clinical Practice, 54(3), 161 - 169.
    • Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, Polman CH, Stevenson VL, McDonald WI (2000). Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Annals of Neurology, 47(6), 831 - 835.
    • Werring DJ, Toosy AT, Clark CA, Parker GJM, Barker GJ, Miller DH, Thompson AJ (2000). Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. Journal of Neurology, Neurosurgery and Psychiatry, 69(2), 269 - 272.
    • Richardson D, Sheean G, Werring DJ, Desai M, Edwards S, Greenwood RJ, Thompson AJ (2000). Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. Journal of Neurology, Neurosurgery and Psychiatry, 69(4), 499 - 506.
    • Hobart JC, Freeman JA, Thompson AJ (2000). Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain, 123, 1027 - 1040.
    • Brex PA, Parker GJM, Leary SM, Molyneux PD, Barker GJ, Davie CA, Thompson AJ, Miller DH (2000). Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. Journal of Neurology, Neurosurgery and Psychiatry, 68(5), 627 - 632.
    • Griffin CM, Parker GJM, Barker GJ, Thompson AJ, Miller DH (2000). MTR and T1 provide complementary information in MS NAWM, but not in lesions. Multiple Sclerosis, 6(5), 327 - 331.
    • Thompson AJ (2000). Multidisciplinary approach. In Hawkins CP, Wolinsky JS (Ed.), Principles of treatment in multiple sclerosis (pp. 299 - 315). : Butterworth-Heinemann.
    • Toosy AT, Thompson AJ (2000). Multiple sclerosis: the disease and its treatment. Pharmaceutical Journal, 264, 694 - 700.
    • Thompson AJ (2000). Neurological rehabilitation: from mechanisms to management. Journal of Neurology, Neurosurgery and Psychiatry, 69(6), 718 - 722.

    1999

    • Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Polman CH, Rovira A, De Sa J, Thompson AJ (1999). Primary and transitional progressive MS: a clinical and MRI cross- sectional study. Neurology, 52(4), 839 - 845.
    • Leary SM, Parker GJM, Stevenson VL, Barker GJ, Miller DH, Thompson AJ (1999). Reproducibility of magnetic resonance imaging measurements of spinal cord atrophy: the role of quality assurance. Magnetic Resonance Imaging, 17, 773 - 776.
    • Pfennings L, Cohen L, Miller D, Gerbaud L, Vleugels L, Freeman J, Vernay D, Biolay S, Ketelaer P, Thompson A, Polman C, van der Ploeg H (1999). Using the short form-36 with multiple sclerosis patients in five countries: a cross cultural comparison. Psychological Reports, 85, 19 - 31.
    • Werring DJ, Clark CA, Parker GJM, Miller DH, Thompson AJ, Barker GJ (1999). A direct demonstration of both structure and function in the visual system: Combining diffusion tensor imaging with functional magnetic resonance imaging. NeuroImage, 9(3), 352 - 361. doi:10.1006/nimg.1999.0421
    • Thompson AJ (1999). Measuring handicap in multiple sclerosis. Multiple Sclerosis, 5(4), 260 - 262.
    • Leary SM, Davie CA, Parker GJM, Stevenson VL, Wang LQ, Barker GJ, Miller DH, Thompson AJ (1999). 1H-Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. Journal of Neurology, 246, 1023 - 1026.
    • van Waesberghe JHTM, Kamphorst W, De Groot CJA, van Walderveen MAA, Castelijns JA, Ravid R, Nijeholt GJLA, van der Valk P, Polman CH, Thompson AJ, Barkhof F (1999). Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Annals of Neurology, 46(5), 747 - 754.
    • Thompson AJ (1999). Benign multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 67, 138 - .
    • Richardson D, Thompson AJ (1999). Botulinum toxin: its use in the treatment of acquired spasticity in adults. Physiotherapy, 85(10), 541 - 551.
    • Thompson AJ (1999). Case 11. In Wills AJ, Marsden CD (Ed.), Fifty neurological cases from the National Hospital (pp. 33 - 35). : Martin Dunitz.
    • Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Borras C, Auriacombe S, Brochet B, Falautano M, Filippi M, Herisse-Dulo L, Montalban X, Parrcira E, Polman CH, Desa J, Langdon DW (1999). Cognitive function in primary progressive and transitional progressive multiple sclerosis - a controlled study with MRI correlates. Brain, 122, 1341 - 1348.
    • Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson AJ, Willoughby E (1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain, 122, 871 - 882.
    • Thompson AJ (1999). Inequality in the availability of expensive treatments. Journal of the Royal College of Physicians of London, 33, 448 - 449.
    • Leary SM, Silver NC, Stevenson VL, Barker GJ, Miller DH, Thompson AJ (1999). Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis. Multiple Sclerosis, 5, 313 - 316.
    • Richardson D, Thompson AJ (1999). Management of spasticity in hereditary spastic paraplegia. Physiotherapy Research International, 4(1), 68 - 76.
    • van der Putten JJMF, Hobart JC, Freeman JA, Thompson AJ (1999). Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel Index and the Functional Independence Measure. Journal of Neurology, Neurosurgery and Psychiatry, 66(4), 480 - 484.
    • Langdon DW, Thompson AJ (1999). Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Multiple Sclerosis, 5, 94 - 100.
    • Brex PA, O'Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, Miller DH (1999). Multi-sequence MRI in clinically isolated syndromes and the early development of MS. Neurology, 53, 1184 - 1190.
    • Miller DH, Thompson AJ (1999). Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. Philosophical Transactions of the Royal Society B: Biological Sciences, 354, 1687 - 1695.
    • Leary SM, Stevenson VL, Miller DH, Thompson AJ (1999). Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis. Journal of Neurology, 246, 562 - 568.
    • Polman CH, Miller DH, McDonald WI, Thompson AJ (1999). Treatment recommendations for interferon-beta in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 67, 561 - 564.
    • Sailer M, O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, McDonald WI, Miller DH (1999). Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology, 52, 599 - 606.
    • Grimaud J, Barker GJ, Wang L, Lai M, MacManus DG, Webb SL, Thompson AJ, McDonald WI, Tofts PS, Miller DH (1999). Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study. Journal of Neurology, 246, 961 - 967.
    • Foong J, Rozewicz L, Davie CA, Thompson AJ, Miller DH, Ron MA (1999). Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. Journal of Neuropsychiatry and Clinical Neurosciences, 11, 45 - 50.
    • Thompson AJ (1999). Differences between primary and secondary progressive multiple sclerosis. In Siva A, Kesselring J, Thompson AJ (Ed.), Frontiers in multiple sclerosis, vol 2 (pp. 29 - 36). : Martin Dunitz.
    • Werring DJ, Clark CA, Barker GJ, Thompson AJ, Miller DH (1999). Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology, 52, 1626 - 1632.
    • Davie CA, Silver NC, Barker GJ, Tofts PS, Thompson AJ, McDonald WI, Miller DW (1999). Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?. Journal of Neurology, Neurosurgery and Psychiatry, 67, 710 - 715.
    • Thompson AJ, Richardson D, Sheehan G, Desai M, Werring D, Edwards S, Greenwood R (1999). Evaluating the role of botulinum toxin type A in adults with focal spasticity. European Journal of Neurology, 6, S75 - .
    • Freeman JA, Langdon DW, Hobart JC, Thompson AJ (1999). Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?. Neurology, 52(1), 50 - 56.
    • Thompson AJ, McDonald WI (1999). Key advances in the effective management of multiple sclerosis.

    1998

    • Werring DJ, Clark CA, Barker GJ, Miller DH, Parker GJM, Brammer MJ, Bullmore ET, Giampietro VP, Thompson AJ (1998). The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in a traumatic injury of the internal capsule. Journal of Neurology, Neurosurgery and Psychiatry, 65(6), 863 - 869.
    • O'Riordan JI, Thompson AJ, Kingsley DPE, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH (1998). The prognostic value of brain MRI in clinically isolated syndromes of the CNS - a 10-year follow-up. Brain, 121, 495 - 503.
    • Kidd D, Thompson PD, Day BL, Rothwell JC, Kendall BE, Thompson AJ, Marsden CD, McDonald WI (1998). Central motor conduction time in progressive multiple sclerosis - correlations with MRI and disease activity. Brain, 121, 1109 - 1116.
    • Werring DJ, Thompson AJ (1998). Improving the quality of life of patients with multiple sclerosis: diagnosis. Drugs of Today, 34, 145 - 156.
    • Werring DJ, Thompson AJ (1998). Medical and surgical treatment of spasticity. In Sheean G (Ed.), Spasticity Rehabilitation (pp. 91 - 107). : Churchill Communications Europe.
    • Gawne-Cain ML, O'Riordan JI, Coles A, Newell B, Thompson AJ, Miller DH (1998). MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences. Journal of Neurology, Neurosurgery and Psychiatry, 64, 197 - 203.
    • Thompson AJ (1998). Multiple sclerosis. In Swash M (Ed.), Outcomes in neurological and neurosurgical disorders (pp. 239 - 266). : Cambridge University Press.
    • Thompson AJ, Hobart JC (1998). Multiple sclerosis: assessment of disability and disability scales. Journal of Neurology, 245, 189 - 196.
    • van Walderveen MAA, Barkhof F, Polman C, Frequin STFM, Hommes OR, Thompson AJ, Valk J (1998). Patterns of brain magnetic resonance abnormalities on T-2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study. European Neurology, 40, 91 - 98.
    • Kappos L, Polman C, Pozzilli C, Thompson A, Dahlke F, Knight R, Hern J, Coleman R, Gerrie L, Cooper G, Moore J, Boringa J, van Oosten B, Ronner H, Schrijver H, Truyen L, Montalban J, Rio J, Tintore M, Jacas C, Marzo E, Lechner-Scott J, Huber S, Lienert C, Brunnschweiler H, Hawkins S, Droogan A, McDonnell G, Duddy M, McKinstry S, Altenkirch H, Baum K, Einhaupl K, Marx P, Poewe W, Walter G, Akman H, Brockmeier B, Scherer P, Zschenderlein R, Schmierer K, Gelderblom H, Hartmann A, Stapf C, Luschow A, Mackert B, Schumacher H, Masuhr F, Hempel T, Zimmermann R, Munch M, Francis D, Heafield M, Al-Memar A, Winer J, Chong M, Brochet B, Gayou A, Auriacombe S, Dousset V, Wiles C, Thomas F, Pickersgill T, Hinds N, Dawson K, Hughes T, Hutchinson M, Murphy R, Redmond J, Webb S, Stoll G, Jander S, Hagemann G, Koller H, Hanemann C, Kolmel H, Reichel D, Petereit K, Thieme A, Khatami A, Neumann M, Amaducci L, Massacesi L, Siracusa G, Amato M, Bartolozzi L, Repice A, Minderhoud J, De Keyser J, Zorgdrager A, Zwanikken C, Poser S, Polak T, Gunther A, Bitsch A, Borner T, Weber F, Wikstrom J, Farkkila M, Majuri H, Sumelahti M, Telakivi T, Fredrikson S, Martin C, Miller D, O'Riordan J, Brex P, Kapoor R, Werring D, Confavreux C, Brunet P, Hannoun D, Brudon F, Moreau T, Blanc S, D'Hooghe M, Jacobs K, Lissoir F, Demonty L, Comi G, Colombo B, Rossi P, Rodegher M, Santuccio G, Martinelli F, Hohlfeld R, Walther E, Goebels N, Dang T, Lindert R, Voltz R, Cartlidge N, Bates D, Moran G, Pandit L, Westwood M, Haller P, Sommer J, Bitter J, Suss F, Mellies J, Mucha P, Lyon-Caen O, Degos JD, Roullet E, Lubetzki C, Creange A, Tourbah A, Pez D, Lecanuet P, Nicolt P, Edan G, Belliard S, De Marco O, Cahagne V, De Burghgraeve V, Brunet I, Fieschi C, Millefiorini E, Gasperini C, Buttinelli C, Frontini M, Howell S, Hadjivassiliou M, Gibson A, Graham A, Harkness K, Lawden M, Clanet M, Wauban E, zais-Vuillemin C, Lau G, Louis C, Panelius M, Ruutiainen J, Eralinna J, Soilu-Hanninen M, Gold R, Hartung HP, Jung S, Bayas A, Flachenecker P, Weilbach F, Archelos J, Kollegger H, Vass K, Asenbaum S, Chatsakos T, Beckmann K, Ghazi M, Wagner K, Miltenburger C, McFarland H, Petkau J, Sabouraud O, Toyka K (1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. The Lancet, 352(9139), 1491 - 1497.
    • Thompson AJ (1998). Rehabilitation in multiple sclerosis. European Journal of Neurology, 5 (S2)(suppl 2), S27 - S28.
    • Tubridy N, Coles AJ, Molyneux P, Compston DAS, Barkhof F, Thompson AJ, McDonald WI, Miller DH (1998). Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain, 121, 225 - 231.
    • Thompson AJ (1998). Spasticity rehabilitation: a rational approach to clinical management. In Sheean G (Ed.), Spasticity Rehabilitation (pp. 51 - 56). : Churchill Communications Europe.
    • Stevenson VL, Leary SM, Losseff NA, Parker GJM, Barker GJ, Husmani Y, Miller DH, Thompson AJ (1998). Spinal cord atrophy and disability in MS - a longitudinal study. Neurology, 51, 234 - 238.
    • Thompson AJ (1998). The use of interferon-  in the treatment of multiple sclerosis: how big a step in the right direction?. Current Practice of Medicine, 1(1), 15 - 17.
    • Foong J, Rozewicz L, Quaghebeur G, Thompson AJ, Miller DH, Ron MA (1998). Neuropsychological deficits in multiple sclerosis after acute relapse. Journal of Neurology, Neurosurgery and Psychiatry, 64, 529 - 532.
    • Kappos L, Polman C, Pozzilli C, Thompson A, Dahlke F, Knight R, Hern J, Coleman R, Gerrie L, Cooper G, Moore J, Boringa J, van Oosten B, Ronner H, Schrijver H, Truyen L, Montalban J, Rio J, Tintore M, Jacas C, Marzo E, Lechner-Scott J, Huber S, Lienert C, Brunnschweiler H, Hawkins S, Droogan A, McDonnell G, Duddy M, McKinstry S, Altenkirch H, Baum K, Einhaupl K, Marx P, Poewe W, Walter G, Akman H, Brockmeier B, Scherer P, Zschenderlein R, Schmierer K, Gelderblom H, Hartmann A, Stapf C, Luschow A, Mackert B, Schumacher H, Masuhr F, Hempel T, Zimmermann R, Munch M, Francis D, Heafield M, Al-Memar A, Winer J, Chong M, Brochet B, Gayou A, Auriacombe S, Dousset V, Wiles C, Thomas F, Pickersgill T, Hinds N, Dawson K, Hughes T, Hutchinson M, Murphy R, Redmond J, Webb S, Stoll G, Jander S, Hagemann G, Koller H, Hanemann C, Kolmel H, Reichel D, Petereit K, Thieme A, Khatami A, Neumann M, Amaducci L, Massacesi L, Siracusa G, Amato M, Bartolozzi L, Repice A, Minderhoud J, De Keyser J, Zorgdrager A, Zwanikken C, Poser S, Polak T, Gunther A, Bitsch A, Borner T, Weber F, Wikstrom J, Farkkila M, Majuri H, Sumelahti M, Telakivi T, Fredrikson S, Martin C, Miller D, O'Riordan J, Brex P, Kapoor R, Werring D, Confavreux C, Brunet P, Hannoun D, Brudon F, Moreau T, Blanc S, D'Hooghe M, Jacobs K, Lissoir F, Demonty L, Comi G, Colombo B, Rossi P, Rodegher M, Santuccio G, Martinelli F, Hohlfeld R, Walther E, Goebels N, Dang T, Lindert R, Voltz R, Cartlidge N, Bates D, Moran G, Pandit L, Westwood M, Haller P, Sommer J, Bitter J, Suss F, Mellies J, Mucha P, Lyon-Caen O, Degos JD, Roullet E, Lubetzki C, Creange A, Tourbah A, Pez D, Lecanuet P, Nicolt P, Edan G, Belliard S, De Marco O, Cahagne V, De Burghgraeve V, Brunet I, Fieschi C, Millefiorini E, Gasperini C, Buttinelli C, Frontini M, Howell S, Hadjivassiliou M, Gibson A, Graham A, Harkness K, Lawden M, Clanet M, Wauban E, Azais-Vuillemin C, Lau GKK, Louis C, Panelius M, Ruutiainen J, Eralinna J, Soilu-Hanninen M, Gold R, Hartung HP, Jung S, Bayas A, Flachenecker P, Weilbach F, Archelos J, Kollegger H, Vass K, Asenbaum S, Chatsakos T, Beckmann K, Ghazi M, Wagner K, Miltenburger C, McFarland H, Petkau J, Sabouraud O, Toyka K, Eur Study Grp Interferon Beta-1b Sec (1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. LANCET, 352(9139), 1491 - 1497.
    • Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, Pregnancy Multiple Sclerosis Grp (1998). Rate of pregnancy-related relapse in multiple sclerosis. NEW ENGL J MED, 339(5), 285 - 291.
    • Sheean GL, Murray NMF, Rothwell JC, Miller DH, Thompson AJ (1998). An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain, 121(5), 967 - 975.
    • Tubridy N, Ader HJ, Barkhof F, Thompson AJ, Miller DH (1998). Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. Journal of Neurology, Neurosurgery and Psychiatry, 64, 50 - 55.
    • Thompson AJ (1998). Identification of brain atrophy with MRI in MS. Multiple Sclerosis, 4, 257 - 259.
    • Stevenson VL, Moseley IF, Phatouros CC, MacManus DG, Thompson AJ, Miller DH (1998). Improved imaging of the spinal cord in multiple sclerosis using three-dimensional fast spin echo. Neuroradiology, 40, 416 - 419.
    • Freeman JA, Thompson AJ (1998). Inpatient rehabilitation in MS.. International MS Journal, 5(1), 16 - 23.
    • Thompson AJ (1998). Multiple sclerosis: rehabilitation measures. Seminars in Neurology, 18(3), 397 - 403.
    • Thompson AJ (1998). Neurorehabilitation. In Marsden CD, Fowler TJ (Ed.), Clinical Neurology (pp. 418 - 423). : Arnold.
    • Hatch J, Johnson J, Thompson A (1998). Standards of health care for people with multiple sclerosis. MS Management, 5(1), 16 - 23.
    • Thompson AJ (1998). Symptomatic treatment in multiple sclerosis. Current Opinion in Neurology, 11, 305 - 309.
    • Stevenson VL, Thompson AJ (1998). The management of multiple sclerosis: current and future therapies. Drugs of Today, 34(3), 267 - 282.
    • O'Riordan JI, Losseff NA, Phatouros C, Thompson AJ, Moseley IF, MacManus DG, McDonald WI, Miller DH (1998). Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. Journal of Neurology, Neurosurgery and Psychiatry, 64, 353 - 357.
    • Rossiter DA, Edmondson A, al-Shahi R, Thompson AJ (1998). Integrated care pathways in multiple sclerosis rehabilitation: completing the audit cycle. Multiple Sclerosis, 4(2), 85 - 89.

    1997

    • Llewellyn-Smith N, Lai M, Miller DH, Rudge P, Thompson AJ, Cuzner ML (1997). Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM- T412. Neurology, 48, 810 - 816.
    • Sheean GL, Murray NMF, Rothwell JC, Miller DH, Thompson AJ (1997). An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain, 120, 299 - 315.
    • Foong J, Rozewicz L, Quaghebeur G, Davie CA, Kartsounis LD, Thompson AJ, Miller DH, Ron MA (1997). Executive function in multiple sclerosis - the role of frontal lobe pathology. Brain, 120, 15 - 26.
    • Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH (1997). H-1 magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 63, 736 - 742.
    • McDonald WI, Thompson AJ (1997). How many kinds of multiple sclerosis are there?. In Thompson AJ, Polman CH, Hohlfeld R (Ed.), Multiple sclerosis: clinical challenges and controversies (pp. 35 - 42). : Martin Dunitz.
    • Stevenson VL, Gawne-Cain ML, Barker GJ, Thompson AJ, Miller DH (1997). Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast flair and fast spin echo. Journal of Neurology, 244, 119 - 124.
    • Playford ED, Rossiter D, Werring DJ, Thompson AJ (1997). Integrated care pathways: evaluating inpatient rehabilitation in stroke. British Journal of Therapy and Rehabilitation, 4, 97 - 102.
    • Freeman JA, Thompson AJ (1997). Is inpatient rehabilitation effective in multiple sclerosis?. In Thompson AJ, Polman CH, Hohlfeld R (Ed.), Multiple sclerosis: clinical challenges and controversies (pp. 313 - 324). : Martin Dunitz.
    • Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, Miller DH, Feldmann M, Thompson EJ (1997). Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology, 48, 1557 - 1565.
    • Miller DH, Kesselring J, McDonald WI, Paty DW, Thompson AJ (1997). Magnetic resonance imaging in multiple sclerosis.
    • Silver NC, Barker GJ, Losseff NA, Gawne-Cain ML, MacManus DG, Thompson AJ, Miller DH (1997). Magnetisation transfer ratio measurement in the cervical spinal cord: a preliminary study in multiple sclerosis. Neuroradiology, 39, 441 - 445.
    • Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Colleluori A, Millefiorini E, Thompson AJ, Horsfield MA, Galgani S, Bozzao L, Fieschi C (1997). The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurologica Scandinavica, 95, 201 - 207.
    • Kesselring J, Thompson AJ (1997). Spasticity, ataxia and fatigue in multiple sclerosis. BAILLIERE CLIN NEUR, 6(3), 429 - 445.
    • Wang L, Lai HM, Thompson AJ, Miller DH (1997). Survey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load. Journal of Neurology, Neurosurgery and Psychiatry, 63(4), 452 - 455.
    • Hobart J, Thompson A (1997). A comparison of two neurologic scoring instruments for multiple sclerosis. J NEUROL, 244(1), 60 - 60.
    • Hobart JC, Thompson AJ (1997). Clinical trials of multiple sclerosis. In Reder AT (Ed.), Interferon therapy of multiple sclerosis (pp. 499 - 508). : Marcel Dekker.
    • Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thompson AJ, Keir GF, Feldmann M, Thompson EJ (1997). Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain, 120, 1 - 13.
    • Foong J, Rozewicz L, Thompson AJ, Miller DH, Ron MA (1997). Frontal lobe disturbances and cognitive functioning in patients with multiple sclerosis. In Ketelaer P, Prosiegel M, Battaglia M, Messmer Uccelli M (Ed.), A problem-oriented approach to multiple sclerosis (pp. 88 - 94). : Acco.
    • Koudriavtseva T, Thompson AJ, Fiorelli M, Gasperini C, Bastianello S, Bozzao A, Paolillo A, Pisani A, Galgani S, Pozzilli C (1997). Gadolinium enahnced MRI predicts clinical amd MRI disease activity in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 62, 285 - 287.
    • Gawne-Cain ML, O'Riordan JI, Thompson AJ, Moseley IF, Miller DH (1997). Multiple sclerosis lesion detect in the brain: a comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo. Neurology, 49, 364 - 370.
    • Thompson AJ, Polman CH, Hohlfeld R (1997). Multiple sclerosis: clinical challenges and controversies.
    • Manji H, McAllister RH, Connolly S, Thompson AJ (1997). Neurologial complications of HIV infection and AIDS. In Millar AB (Ed.), Medical management of HIV and AIDS (pp. 117 - 156). : Springer Verlag.
    • Thompson AJ (1997). Pathogenesis and mechanisms of disability. In Miller DH, Kesselring J, Thompson AJ, McDonald WI, Paty DW (Ed.), Magnetic resonance in multiple sclerosis (pp. 126 - 146). : Cambridge University Press.
    • Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, Montalban X, Desa J (1997). Primary progressive multiple sclerosis. Brain, 120, 1085 - 1096.
    • Kidd D, Thompson AJ (1997). Prospective study of neurorehabilitation in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 62, 423 - 424.
    • Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin FD, Miller A, Petkau J, Rao S, Reingold SC, Syndulko K, Thompson AJ, Wallenberg J, Weinshenker B, Willoughby E (1997). Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Annals of Neurology, 43, 379 - 382.
    • Thompson AJ (1997). Rehabilitation solutions in Multiple Sclerosis. Schweizer Archiv für Neurologie und Psychiatrie, 148(5), 182 - 186.
    • Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH (1997). Sensitivity of contrast enhanced MRI in multiple sclerosis: effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain, 120, 1149 - 1161.
    • Lai HM, Davie CA, Gass A, Barker GJ, Webb S, Tofts PS, Thompson AJ, McDonald WI, Miller DH (1997). Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis. Journal of Neurology, 244, 308 - 311.
    • Barkhof F, Filippi M, Miller DH, Tofts PS, Kappos L, Thompson AJ (1997). Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. Journal of Neurology, 244, 76 - 84.
    • Richardson D, Edwards S, Sheean GL, Greenwood RJ, Thompson AJ (1997). The effect of botulinum toxin on hand function after incomplete spinal cord injury at the level of C5/6: a case report. Clinical Rehabilitation, 11, 288 - 292.
    • Freeman JA, Langdon DW, Hobart JC, Thompson AJ (1997). The impact of inpatient rehabilitation on progressive multiple sclerosis. Annals of Neurology, 42, 236 - 244.
    • Kidd D, Barker GJ, Tofts PS, Gass A, Thompson AJ, McDonald WI, Miller DH (1997). The transverse magnetisation decay characteristics of longstanding lesions and normal appearing white matter in multiple sclerosis. Journal of Neurology, 244, 125 - 130.
    • van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Ader HJ, Polman CH (1997). Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology, 49, 351 - 357.
    • Langdon DW, Thompson AJ (1997). Emotion and insight in multiple sclerosis. In Ketelaer P, Prosiegel M, Battaglia M, Messmer U (Ed.), A problem-oriented approach to multiple sclerosis (pp. 142 - 149). : Acco.

    1996

    • Rovaris M, Barnes D, Woodroofe N, du Boulay EPGH, Thorpe JW, Thompson AJ, McDonald WI, Miller DH (1996). Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium enhanced brain MRI and cytokine measurement in different clinical subgroups. Journal of Neurology, 243, 536 - 542.
    • Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ (1996). Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain, 119, 2009 - 2019.
    • Johnson J, Thompson A (1996). Rehabilitation in a neuroscience centre: the role of expert assessment and selection. British Journal of Therapy and Rehabilitation, 3, 303 - 308.
    • Thompson AJ (1996). Rehabilitation of progressive neurological disorders: a worthwhile challenge. Current Opinion in Neurology, 9, 437 - 440.
    • Playford ED, Maserei A, Thompson AJ (1996). The nature and management of swallowing difficulties in MS. In Charlier M, Ketelaer P (Ed.), Communication and swallowing disorders (pp. 101 - 104). : AIFM.
    • Thompson AJ, McDonald WI (1996). Multiple sclerosis. Medicine (Oxford), 24, 69 - 75.
    • Thompson AJ (1996). Multiple sclerosis: Symptomatic treatment. Journal of Neurology, 243, 559 - 565.
    • Thompson AJ, Noseworthy JH (1996). New treatments for multiple sclerosis: a clinical perspective. Current Opinion in Neurology, 9, 187 - 198.
    • Paty DW, Goodkin D, Thompson AJ, Rice G (1996). Guidelines for physicians with patients on IFNá-1b: the use of an assay for neutralizing antibodies (NAB). Neurology, 47, 865 - 866.
    • Stevenson VL, Playford ED, Langdon DW, Thompson AJ (1996). Rehabilitation of incomplete spinal cord pathology: facts affecting prognosis and outcome. Journal of Neurology, 243(9), 644 - 647.
    • Freeman JA, Playford ED, Nicholas RS, Thompson AJ (1996). A neurological rehabilitation unit: audit of activity and outcome. Journal of the Royal College of Physicians of London, 30(1), 21 - 26.
    • Scrutton J, Edwards S, Sheean G, Thompson A (1996). A little bit of toxin does you good?. Physiotherapy Research International, 1(3), 141 - 147.
    • Losseff NA, Kingsley DPE, McDonald WI, Miller DH, Thompson AJ (1996). Clinical and magnetic resonance imaging predictors of disability in primary and secondary multiple sclerosis. Multiple Sclerosis, 1, 218 - 222.
    • Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin FD, Miller A, Petkau J, Rao SM, Reingold SC, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E (1996). Clinical outcomes assessment in multiple sclerosis. Annals of Neurology, 40, 469 - 479.
    • Thompson AJ (1996). Clinical review of multiple sclerosis. Clinical Immunotherapeutics, 5(supplement), 1 - 11.
    • Langdon DW, Thompson AJ (1996). Cognitive problems in multiple sclerosis. MS Management, 3, 1 - 9.
    • Langdon DW, Thompson AJ (1996). Emotion and insight in multiple sclerosis. In Prosiegel M, Vermote R, Ketelaer P (Ed.), Neuropsychology and psychology (pp. 97 - 106). : AISM Genova.
    • Foong J, Rozewicz L, Thompson AJ, Miller DH, Ron MA (1996). Frontal lobe disturbances and cognitive functioning in patients with multiple sclerosis. In Prosiegel M, Vermote R, Ketelaer P (Ed.), Neuropsychology and psychology (pp. 45 - 52). : AISM Genova.
    • Freeman JA, Langdon DW, Hobart JC, Thompson AJ (1996). Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation. Journal of Neurologic Rehabilitation, 10, 185 - 194.
    • Gasperini C, Horsfield MA, Thorpe JW, Kidd D, Barker GJ, Tofts PS, MacManus DG, Thompson AJ, Miller DH, McDonald WI (1996). Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. Journal of Magnetic Resonance Imaging, 6(4), 580 - 584.
    • Filippi M, Watts P, Eaton L, Honer J, McDonald WI, Thompson AJ (1996). Mark VII Microclimate System (cooling suit) in the symptomatic treatment of multiple sclerosis patients with marked temperature sensitivity. Argomenti di Neurologia, 5, 162 - 165.
    • Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI, Thompson AJ (1996). MRI dynamics of brain and spinal cord in progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 60, 15 - 19.
    • Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ (1996). Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain, 119(3), 701 - 708.
    • Freeman JA, Hobart JC, Thompson AJ (1996). Outcomes-based research in neurorehabilitation: The need for multidisciplinary team involvement. Disability and Rehabilitation, 18, 106 - 110.
    • Rozewicz L, Langdon DW, Davie CA, Thompson AJ, Ron MA (1996). Resolution of left hemisphere cognitive dysfunction in multiple sclerosis with magnetic resonance correlates: a case report. Cognitive Neuropsychiatry, 1, 17 - 25.
    • Thorpe JW, Kidd D, Moseley IF, Kendall BE, Thompson AJ, MacManus DG, McDonald WI, Miller DH (1996). Serial gadolinium enhanced MRI of the brain and spinal cord in early relapsing remitting multiple sclerosis. Neurology, 46, 373 - 378.
    • Thompson AJ, Johnston S, Harrison J, Sheil R, Burnard S (1996). Service delivery in multiple sclerosis: the need for co-ordinated community care. MS Management, 4, 11 - 18.
    • Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ, Keir GF, Miller DH, Feldmann M, Thompson EJ (1996). Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. Journal of Neurology, Neurosurgery and Psychiatry, 60, 20 - 26.
    • Thorpe JW, Kidd D, Moseley IF, Thompson AJ, MacManus DG, Compston DAS, McDonald WI, Miller DH (1996). Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain, 119, 709 - 714.
    • van Oosten BW, Lai M, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Hodgkinson S, Polman CH (1996). A phase II trial of anti-CD4-antibodies in the treatment of multiple sclerosis. Multiple Sclerosis, 1, 339 - 342.
    • Lai M, Hodgson T, Gawne-Cain ML, Webb S, MacManus DG, McDonald WI, Thompson AJ, Miller DH (1996). A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 60, 339 - 341.
    • O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DPE, Thompson EJ, McDonald WI, Miller DH (1996). Clinical, CSF and MRI findings in Devic's neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 60, 382 - 387.
    • Hobart JC, Lamping DL, Thompson AJ (1996). Evaluating neurological outcome measures: the bare essentials. Journal of Neurology, Neurosurgery and Psychiatry, 60, 127 - 130.

    1995

    • THOMPSON AJ (1995). THE FUNCTIONAL INDEPENDENCE MEASURE - A COMPARATIVE VALIDITY AND RELIABILITY STUDY - REPLY. DISABIL REHABIL, 17(8), 456 - 456.
    • Filippi M, Paty DW, Kappos L, Barkhof F, Compston DAS, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH (1995). Correlations between changes in disability and T2 weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology, 45, 255 - 260.
    • Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozzilli C (1995). Inteferon beta-1b in secondary progressive multiple sclerosis - outline of the clinical trial. Multiple Sclerosis, 1, S51 - S54.
    • Rossiter D, Thompson AJ (1995). Introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting. Disability and Rehabilitation, 17, 443 - 448.
    • Freeman JA, Hobart JC, Thompson AJ (1995). Outcomes-based research in neurorehabilitation: the need for multidisciplinary team involvement. Disability and Rehabilitation, 17, 323 - 327.
    • Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH (1995). Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain, 118(6), 1583 - 1592.
    • Jones SJ, Turano G, Kriss A, Shawkat F, Kendall B, Thompson AJ (1995). Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. Journal of Neurology, Neurosurgery and Psychiatry, 59, 260 - 265.
    • Kidd D, Howard RS, Losseff NA, Thompson AJ (1995). The benefit of inpatient neurorehabilitation in multiple sclerosis. Clinical Rehabilitation, 9(3), 198 - 203.
    • Kidd D, Stewart G, Baldry J, Johnson J, Rossiter D, Petruckevitch A, Thompson AJ (1995). The Functional Independence Measure: a comparative validity and reliability study. Disability and Rehabilitation, 17, 10 - 14.
    • Rossiter D, Thompson AJ (1995). Integrated care pathways and their role in the clinical audit of rehabilitation for people with multiple sclerosis. MS Management, 2(2), 1, 9 - 1,18.
    • Stewart G, Kidd D, Thompson AJ (1995). The assessment of handicap: an evaluation of the Environmental Status Scale. Disability and Rehabilitation, 17, 312 - 316.
    • Losseff NA, Thompson AJ (1995). The medical management of increased tone. Physiotherapy, 81, 480 - 484.
    • Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH (1995). Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain, 118(6), 1601 - 1612.

    1994

    • Zoukos Y, Kidd D, Woodroofe MN, Kendall BE, Thompson AJ, Cuzner ML (1994). Increased expression of high affinity IL-2 receptors and beta- adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain, 117, 307 - 315.
    • Gass A, Barker GJ, Kidd D, Thorpe JW, MacManus DG, Brennan A, Tofts PS, Thompson AJ, McDonald WI, Miller DH (1994). Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Annals of Neurology, 36(1), 62 - 67.
    • FILIPPI M, PATY DW, KAPPOS L, BARKHOF F, COMPSTON DAS, THOMPSON AJ, ZHAO GJ, WILES CM, MCDONALD WI, MILLER DH (1994). LONGITUDINAL-STUDY ON CORRELATIONS BETWEEN DISABILITIES AND CEREBRAL MR CHANGES IN MULTIPLE-SCLEROSIS.
    • Nauta JJP, Thompson AJ, Barkhof F, Miller DH (1994). Magnetic-resonance-imaging in monitoring the treatment of multiple-sclerosis patients - statistical power of parallel- groups and crossover designs. Journal of the Neurological Sciences, 122, 6 - 14.
    • Thompson AJ (1994). Management of MS: towards defining a model of care. MS Update, 8, 36 - 38.
    • Thompson AJ, Johnston S (1994). The management of neurological disease. The Clinician in Management, 3(2), 4 - 7.
    • Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI (1994). Benign form of multiple-sclerosis - mri evidence for less frequent and less inflammatory disease-activity. Journal of Neurology, Neurosurgery and Psychiatry, 57, 1070 - 1072.
    • Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI (1994). A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain, 117, 759 - 765.
    • McDonald WI, Miller DH, Thompson AJ (1994). Are MRI resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-. Annals of Neurology, 36(1), 14 - 18.
    • Filippi M, Barker GJ, Horsfield MA, Sacares PR, MacManus DG, Thompson AJ, Tofts PS, McDonald WI, Miller DH (1994). Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. Journal of Neurology, 241(4), 246 - 251.
    • Thompson AJ, Colville PL, Ketelaer P, Paty DW (1994). Long term management of multiple sclerosis. MS Management, 1(1), 1 - 9.
    • Manji H, Connolly S, McAllister RH, Valentine AR, Kendall BE, Fell M, Durrance P, Thompson AJ, Newman S, Weller IV (1994). Serial MRI of the brain in asymptomatic patients infected with HIV: results from the UCMSM/Medical Research Council neurology cohort. Journal of Neurology, Neurosurgery and Psychiatry, 57, 144 - 149.

    1993

    • Thorpe JW, Kidd D, Kendall BE, Tofts PS, Barker GJ, Thompson AJ, MacManus DG, McDonald WI, Miller DH (1993). Spinal-cord MRI using multiarray coils and fast spin-echo .1. technical aspects and findings in healthy-adults. Neurology, 43(12), 2625 - 2631.
    • Barkhof F, Thompson AJ, Kappos L, Nauta JJP, Yousri T, Berry I, Scotti G, Appel B, Tofts PS (1993). Database for serial magnetic resonance imaging in multiple sclerosis. Neuroradiology, 35(5), 362 - 366.
    • Filippi M, Barker GJ, Sacares RP, Thompson A, McDonald I, Miller D (1993). Longstanding lesions and normal appearing white matter in benign and secondary progressive MS: a quantitative MRI study. Schweizer Archiv für Neurologie und Psychiatrie, 114, 330 - 331.
    • Cockburn F, Barwell BE, Brenton DP, Chapple J, Clark B, Curzon G, Davidson DC, Heeley AF, Laing SC, Lister-Cheese IAF, McDonald WI, Malcolm S, Pollitt RJ, Quinn D, Rylance G, Smith I, Stewart A, Surtee R, Thompson AJ, Tyfield L, Whittle MJ (1993). Phenylketonuria due to phenylalanine hydroxylase deficiency:an unfolding story. BMJ (Clinical Research Ed.), 306, 115 - 119.
    • Cockburn F, Barwell BE, Breton DP, Chapple J, Clark B, Curzon G, Davidson DC, Heeley AF, Laing SC, Lister-Cheese IAF, McDonald I, Malcolm S, Pollitt RJ, Quinn D, Rylance G, Smith I, Stewart A, Surtees R, Thompson AJ, Tyfield L, Whittle MJ (1993). Recommendations on the dietary management of phenylketonuria. Archives of Disease in Childhood, 68, 426 - 427.
    • Rakhit RD, Beck RO, Foster O, Thompson AJ, Kellar-Wood HF (1993). Resolution of lower-limb neurological deficit with penile papaverine in spinal arteriovenous malformation. The Lancet, 341, 490 - .
    • Leslie TA, Goldsmith PC, Thompson AJ, Dowd PM (1993). Degos disease and spastic paraplegia. Clinical and Experimental Dermatology, 18, 344 - 346.
    • Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus DG, McDonald WI, Miller DH (1993). Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology, 43, 2632 - 2637.
    • Feinstein A, Ron MA, Thompson AJ (1993). A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. Brain, 116, 569 - 602.
    • Kidd D, Thompson AJ, MacManus DG, Kendall BE, McDonald WI (1993). Benign MS:MRI evidence for a less inflammatory disease. Journal of Neurology, Neurosurgery and Psychiatry, 56, 730 - .
    • FILIPPI M, BARKER GJ, HORSFIELD MA, THOMPSON AJ, MCDONALD IW, MILLER DH (1993). BENIGN MULTIPLE-SCLEROSIS AND SECONDARY PROGRESSIVE MULTIPLE-SCLEROSIS - STUDY USING QUANTITATIVE MAGNETIC-RESONANCE.
    • Thompson AJ, Tillotson S, Smith I, Kellar-Wood HF, Moore SG, Brenton DP (1993). Brain MRI changes in phenylketonuria: associations with dietary status. Brain, 116, 811 - 821.
    • Thompson AJ, Kermode AG, Moseley IF, MacManus DG, McDonald WI (1993). Seizures due to multiple sclerosis: seven patients with MRI correlations. Journal of Neurology, Neurosurgery and Psychiatry, 56, 1317 - 1320.

    1992

    • Thompson AJ, Miller D, Youl B, MacManus DG, Moore S, Kingsley DPE, Kellar-Wood HF, Feinstein A, McDonald WI (1992). Serial gadolinium-enchanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology, 42, 60 - 63.
    • Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1992). MRI in monitoring the treatment of multiple sclerosis:concerted action guidelines. Journal of Neurology, Neurosurgery and Psychiatry, 55, 978 - .
    • Thompson AJ, McDonald WI (1992). Multiple sclerosis and its pathophysiology. In Asbury AK, McKhann GM, McDonald WI (Ed.), Diseases of the nervous system:clinical neurobiology (pp. 1209 - 1228). : Saunders.
    • Thompson AJ, Miller DH (1992). Magnetic resonance imaging in clinical practice. In Kennard C (Ed.), Recent advances in clinical neurology. No.7 (pp. 199 - 219). : Churchill Livingstone.
    • Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, Moseley IF, McDonald WI (1992). High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. Journal of Neurology, Neurosurgery and Psychiatry, 55, 450 - 453.
    • Zoukos Y, Leonard JP, Thomaides TN, Thompson AJ, Cuzner ML (1992). Beta adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Annals of Neurology, 31, 657 - 662.
    • Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ (1992). EDMUS, a European database for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 55, 671 - 676.
    • Hawkins CP, Thompson AJ (1992). Recent advances in neurology. In Kaufman L (Ed.), Anaesthesia review 9 (pp. 145 - 157). : Churchill Livingstone.

    1991

    • Francis DA, Thompson AJ, Brookes P, Davey N, Lechler RI, McDonald WI, Batchelor JR (1991). Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ?. Hum Immunol, 32(2), 119 - 124.
    • Cadoux-Hudson TAD, Kermode AG, Rajagopalan B, Taylor D, Thompson AJ, Ormerod IE, McDonald WI, Radda GK (1991). Biochemical changes within a multiple sclerosis plaque in vivo. Journal of Neurology, Neurosurgery and Psychiatry, 54, 1004 - 1006.
    • Thompson AJ, Smith I, Kendall BE, Youl BD, Brenton DP (1991). Magnetic resonance imaging changes in early treated patients with phenylketonuria. The Lancet, 337, 1224 - .
    • Kermode AG, Rudge P, Thompson AJ, du Boulay EPGH, McDonald WI (1991). MRI of thoracic cord in tropical spastic paraparesis. Journal of Neurology, Neurosurgery and Psychiatry, 54, 1110 - 1111.
    • Wroe SJ, Thompson AJ, McDonald WI (1991). Painful intraorbital meningiomas. Journal of Neurology, Neurosurgery and Psychiatry, 54, 1009 - 1010.
    • Thompson AJ, McDonald WI (1991). The diagnosis of primary progressive multiple sclerosis. In Wieth lter H, Dichgans J, Mertin J (Ed.), Current concepts in multiple sclerosis. Proceedings of the 6th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) T_bingen, 11-13 October 1990 (pp. 43 - 46). : Excerpta Medica.
    • Youl BD, Kermode AG, Thompson AJ, Revesz T, Scaravilli F, Barnard RO, Kirkham FJ, Kendall BE, Kingsley DPE, Moseley IF, Stevens JM, Earl CJ, McDonald WI (1991). Destructive lesions in demyelinating disease. Journal of Neurology, Neurosurgery and Psychiatry, 54, 288 - 292.
    • Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991). Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. Journal of Neurology, Neurosurgery and Psychiatry, 54, 683 - 688.
    • Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DPE, McDonald WI (1991). Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Annals of Neurology, 29, 53 - 62.
    • Thompson AJ (1991). Sarcoidosis and the nervous system. In Swash M, Oxbury J (Ed.), Clinical neurology (pp. 1725 - 1731). : Churchill Livingstone.

    1990

    • Kermode AG, Thompson AJ, MacManus DG, Moore SG, McDonald WI (1990). Duration of enhancement in secondary progessive MS. In (Ed.), Society of Magnetic Resonance in Medicine. 9th Annual scientific meeting and exhibition, New York. Book of abstracts (pp. 622 - ). : .
    • Thompson AJ, Kermode AG, MacManus DG, Moore SG, Moseley IF, Kingsley DPE, Kendall BE, McDonald WI (1990). Gadolinium-enhancement in multiple sclerosis: pathological and clinical significance. In (Ed.), Society of Magnetic Resonance in Medicine. 9th Annual scientific meeting and exhibition, New York. Book of abstracts (pp. 339 - ). : .
    • Thompson AJ, Youl BD, Moore DG, MacManus DG, Smith I, Brenton DP, Kendall BE (1990). MRI in phenylketonuria: abnormalities in young adults with late onset neurological disability. In (Ed.), Society of Magnetic Resonance in Medicine. 9th Annual scientific meeting and exhibition, New York. Book of abstracts (pp. 623 - ). : .
    • Kermode AG, Rudge P, Thompson AJ, du Boulay EPGH, McDonald WI (1990). MRI of thoracic cord in tropical spastic paraparesis. Journal of Neurology, Neurosurgery and Psychiatry, 53, 710 - .
    • Thompson AJ, Miller DH, MacManus DG, McDonald WI (1990). Patterns of disease activity in multiple sclerosis. BMJ (Clinical Research Ed.), 301, 44 - 45.
    • Thompson AJ, Smith I, Brenton DP, Youl BD, Rylance G, Davidson DC, Kellar-Wood HF, Lees AJ (1990). Neurological deterioration in young adults with phenylketonuria. The Lancet, 336, 602 - 605.
    • Kermode AG, Wicks D, Barker GJ, Thompson AJ, MacManus DG, Moore SG, Youl B, McDonald WI (1990). T1 and T2 in normal appearing white matter in progressive MS. In (Ed.), Society of Magnetic Resonance in Medicine. 9th Annual scientific meeting and exhibition, New York. Book of abstracts (pp. 621 - ). : .
    • Barry R, Lawrence M, Thompson A, McDonald I, Groome NP (1990). An improved radioimmunoassay for myelin basic protein-like immunoreactive material in cerebrospinal fluid. Neurochemistry International, 16, 549 - 558.
    • Kermode AG, Thompson AJ, Tofts PS, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, Rudge P, McDonald WI (1990). Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain, 113(5), 1477 - 1489.
    • Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, Kingsley DPE, Moseley IF, du Boulay EPGH, McDonald WI (1990). Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology, 40(2), 229 - 235.
    • Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, McDonald WI (1990). Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (Clinical Research Ed.), 300, 631 - 634.

    1989

    • Kermode AG, Rudge P, Thompson AJ, du Boulay EPGH, McDonald WI (1989). MRI of thoracic cord in tropical spastic paraparesis. In (Ed.), Society of Magnetic Resonance in Medicine. 8th Annual scientific meeting and exhibition, Amsterdam. Book of Abstracts (pp. 729 - ). : .
    • BROWN MM, THOMPSON AJ, WEDZICHA JA, SWASH M (1989). SARCOIDOSIS PRESENTING WITH STROKE. STROKE, 20(3), 400 - 405.
    • Thompson AJ, Kermode AG, MacManus DG, Kingsley DPE, Kendall BE, McDonald WI (1989). Patterns of disease activity in MS: an MRI study of brain and spinal cord. In (Ed.), Society of Magnetic Resonance in Medicine. 8th Annual scientific meeting and exhibition, Amsterdam. Book of abstracts (pp. 117 - ). : .
    • Kermode AG, Tofts PS, Thompson AJ, MacManus DG, McDonald WI (1989). Serial changes in multiple sclerosis studied using dynamic Gd-DTPA enhanced MRI. In (Ed.), Society of Magnetic Resonance in Medicine. 8th Annual scientific meeting and exhibition, Amsterdam. Book of abstracts (pp. 732 - ). : .
    • Thompson AJ, Kermode AG, MacManus DG, Kingsley DPE, Kendall BE, McDonald WI (1989). Serial Gd-DTPA MRI reveals differences between primary and secondary progressive multiple sclerosis. In (Ed.), Society of Magnetic Resonance in Medicine. 8th Annual scientific meeting and exhibtion, Amsterdam. Book of abstracts (pp. 724 - ). : .
    • Kermode AG, Tofts PS, Thompson AJ, Rudge P, MacManus DG, Kendall BE, Moseley IF, Kingsley DPE, McDonald WI (1989). Changing activity in ms lesions: an MRI study. In Gonsette RE, Delmotte P (Ed.), Recent advances in multiple sclerosis therapy (pp. 43 - 46). : Excerpta Medica.
    • Thompson AJ, Kermode AG, MacManus DG, Kingsley DPE, Kendall BE, Moseley IF (1989). Pathogenesis of progessive multiple sclerosis. The Lancet, i, 1322 - 1323.
    • Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R, Hughes RAC, Thompson M, Hand J (1989). Relative efficacy of intravenous methylpresnisolone amd ACTH in the treatment of acute relapse in MS. Neurology, 39, 969 - 971.

    1988

    • THOMPSON AJ, BROWN MM, RIDLEY A (1988). ESCHERICHIA-COLI MENINGITIS AND DISSEMINATED STRONGYLOIDIASIS. J NEUROL NEUROSUR PS, 51(12), 1596 - 1597.
    • Ingram DAM, Thompson AJ, Swash M (1988). Central motor conduction in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 51, 487 - 494.
    • Schwartz MS, Swash M, Ingram DAM, Davis GR, Thompson AJ, Thakkar C, Hart G (1988). Patterns of selective involvement of thigh muscles in neuromuscular disease. Muscle and Nerve, 11, 1240 - 1245.
    • Brown MM, Thompson AJ, Goh BT, Forster GE, Swash M (1988). Bell's palsy and HIV infection. Journal of Neurology, Neurosurgery and Psychiatry, 51, 425 - 426.
    • Thurston SE, Leigh RJ, Crawford T, Thompson AJ, Kennard C (1988). Two distinct deficits of visual tracking caused by ubilateral lesions of cerebral cortex in humans. Annals of Neurology, 23, 266 - 273.
    • Thompson AJ, Brown MM, Swash M, Thakkar C, Scholtz CL (1988). Autopsy validation of MRI in central pontine myelinolysis. Neuroradiology, 30, 175 - 177.
    • Thompson AJ, Swash M, Cox EL, Ingram DAM, Gray A, Schwartz MS (1988). Polysaccharide storage myopathy. Muscle and Nerve, 11, 349 - 355.

    1987

    • THOMPSON A, BRAZIL J, HUTCHINSON M, FEIGHERY C (1987). 3 POSSIBLE LABORATORY INDEXES OF DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS. NEUROLOGY, 37(3), 515 - 519.

    1986

    • THOMPSON AJ, HUTCHINSON M, BRAZIL J, FEIGHERY C, MARTIN EA (1986). A CLINICAL AND LABORATORY STUDY OF BENIGN MULTIPLE-SCLEROSIS. Q J MED, 58(225), 69 - 80.
    • THOMPSON AJ, BRAZIL J, WHELAN CA, MARTIN EA, HUTCHINSON M, FEIGHERY C (1986). PERIPHERAL-BLOOD LYMPHOCYTE-T CHANGES IN MULTIPLE-SCLEROSIS - A MARKER OF DISEASE PROGRESSION RATHER THAN OF RELAPSE. J NEUROL NEUROSUR PS, 49(8), 905 - 912.

    1985

    • THOMPSON AJ, BRAZIL J, MARTIN EA, HUTCHINSON M, WHELAN CA, FEIGHERY C (1985). SUPPRESSOR T-CELL CHANGES IN ACTIVE MULTIPLE-SCLEROSIS - ANALYSIS WITH 3 DIFFERENT MONOCLONAL-ANTIBODIES. J NEUROL NEUROSUR PS, 48(10), 1062 - 1064.
    • THOMPSON A, HUTCHINSON M, MANSFIELD M, MARTIN EA (1985). SUSPECTED AND CLINICALLY DEFINITE MULTIPLE-SCLEROSIS - THE RELATIONSHIP BETWEEN CSF IMMUNOGLOBULINS AND CLINICAL COURSE. J NEUROL NEUROSUR PS, 48(6), 604 - 604.
    • THOMPSON AJ, MARTIN EA (1985). THE PACINIAN CORPUSCLE AND SHEKLETON,JOHN. NEUROLOGY, 35(12), 1747 - 1747.
    • THOMPSON AJ, MARTIN EA (1985). DUMAS, ZOLA, AND THE LOCKED-IN SYNDROME - REPLY. NEUROLOGY, 35(7), 1087 - 1087.
    • THOMPSON AJ, HUTCHINSON M (1985). OLIGOCLONAL BANDS IN MULTIPLE-SCLEROSIS - AN INDEX OF DISEASE-ACTIVITY. NEUROLOGY, 35(10), 1533 - 1533.
    • THOMSON AJ, BRAZIL J, FEIGHERY C, WHELAN A, KELLET J, MARTIN EA, HUTCHINSON M (1985). CSF MYELIN BASIC-PROTEIN IN MULTIPLE-SCLEROSIS. ACTA NEUROL SCAND, 72(6), 577 - 583.

    1984

    • MARTIN EA, LAVIN PJ, THOMPSON AJ (1984). PAINFUL EXTREMITIES AND NEUROLOGICAL DISORDER IN ESSENTIAL THROMBOCYTHEMIA. J ROY SOC MED, 77(5), 372 - 374.
    • THOMPSON AJ, HUTCHINSON M (1984). MYOPATHY IN HYPOKALEMIC PERIODIC PARALYSIS - REVERSAL WITH ACETAZOLAMIDE. IRISH MED J, 77(6), 171 - 172.

    • Cano SJ, Thompson AJ (). How to measure the effects of rehabilitation. In Kesselring C, Thompson (Ed.), Recovery in Multiple Sclerosis (pp. - ). : .
    • Abdel-Aziz K, Schneider T, Yiannakas MC, Altmann D, Wheeler-Kingshott CAM, Peters AL, Day BL, Thompson AJ, Ciccarelli O (). Tract-specific Q-space imaging of the cervical cord demonstrated early axonal damage in primary progressive multiple sclerosis.